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 ABSTRACT 
Prostate cancer is the most common cancer among men in developed countries, but it is still 
unclear what causes the disease. Body mass index (BMI) and physical activity are modifiable 
lifestyle factors with the potential to influence the development and progression of prostate tumors 
and may provide alternative strategies for reducing both prostate cancer incidence and mortality.  
 
This thesis includes studies of the importance of body weight and physical activity on prostate 
cancer as well as methodological studies of how to assess physical activity in epidemiological 
studies. In Study I and II we aim to clarify the effect of BMI, weight change and physical activity 
on prostate cancer progression and mortality, while we in Study V aim to investigate the 
associations between BMI, serum prostate specific antigen (PSA) and the risk of prostate cancer. In 
Study III and IV we aim to assess the validity of the new web-based physical activity 
questionnaire Active-Q against three different reference methods. 
 
In Study I and II, we found that high BMI was associated with increased rates of overall mortality, 
but not progression or prostate cancer specific mortality, in men diagnosed with localized prostate 
cancer. An increase in body weight by >5% after diagnosis was associated with a higher prostate 
cancer specific mortality, while a weight reduction by >5% after diagnosis was associated with 
higher overall mortality. Frequent walking/bicycling and exercise were associated with lower 
prostate cancer specific and overall mortality, compared to a less active lifestyle. Moreover, high 
levels of total recreational activity and household work were associated with lower overall 
mortality. Study V showed that men with high BMI had lower serum PSA-levels, compared to 
men with normal BMI. Although BMI was not associated with overall prostate cancer risk, there 
was a suggested association between high BMI and high-grade prostate cancer. 
 
Active-Q was validated with regards to energy expenditure and total MET-hours against doubly 
labelled water and pedometers in Study III and with regards to time spent in different intensity 
levels of activity against accelerometers in Study IV. Active-Q showed moderate validity 
compared to the reference methods and good absolute agreement for energy expenditure while a 
somewhat lower agreement for time at different intensity levels was seen. When comparing 
repeated Active-Q assessments, the questionnaire showed high reproducibility.   
 
In conclusion, a physically active lifestyle after prostate cancer diagnosis is beneficial and 
associated with lower levels of both overall and prostate cancer specific mortality. Our results also 
showed that a large increase in body weight after diagnosis was associated with higher prostate 
cancer specific mortality, whereas weight reduction was associated increased higher overall 
mortality. Although we did not find a clear effect of BMI on overall prostate cancer risk, 
progression or prostate cancer specific mortality, we found that men with high BMI had lower 
levels of serum PSA, potentially hampering early detection of prostate cancer. Weight maintenance 
and a physically active lifestyle after diagnosis may complement prostate cancer treatment to 
improve survival. Also, Active-Q is a valid method for assessing energy expenditure and time 
spent at different intensity levels in future epidemiological studies.  
 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Prostatacancer är den vanligaste cancerformen i Sverige och drabbar omkring 9000 män varje år. 
Överlevnaden är god och fler män dör av hjärt- och kärlsjukdomar än av sin prostatacancer. Vad 
som orsakar sjukdomen är ännu oklart men forskning visar att ålder, etnicitet och ärftliga faktorer 
spelar stor roll. Senare års forskning tyder också på att livsstilsfaktorer är betydelsefulla för risken 
att drabbas av prostatacancer samt för överlevnaden efter diagnos.  
 
Denna avhandling har två huvudsyften. Det första är att studera hur kroppsvikt uttryck som BMI 
(body mass index, kg/m
2
), viktförändring och fysisk aktivitet är kopplat till prostatacancer. Det 
andra syftet är att validera den nya webbenkäten ”Active-Q” som mäter fysisk aktivitet. För att 
kunna studera hur fysisk aktivitet är kopplat till hälsa och sjukdom i framtida studier är det viktigt 
att använda pålitliga mätmetoder.  
 
I avhandlingens första två delstudier (I och II) analyserade vi data från omkring 5000 svenska män 
som fått en prostatcancerdiagnos mellan åren 1997-2002. Detta är den största studien i sitt slag som 
följt en grupp män med prostatacancer och undersökt hur livsstilen påverkar sjukdomens 
utveckling och dödlighet. I den femte delstudien (V) analyserade vi data från drygt 15000 män som 
inte hade prostatacancer vid studiens start. I denna studie undersökte vi sambandet mellan BMI och 
prostatacancerrisk samt kopplingen mellan BMI och den bilogiska markören prostataspecifikt 
antigen (PSA). PSA är ett protein som bildas i prostatan och som normalt finns i mycket små 
mängder i blodet. Vid olika sjukdomar, inklusive prostatacancer, är nivåerna ofta förhöjda och 
PSA-tester används därför för att upptäcka prostatacancer. 
 
I delstudie ett (I) undersökte vi kopplingen mellan BMI vid tiden för diagnos och risken för 
prostatacancerprogression (cancertumörens utveckling). Vi studerade även hur BMI vid diagnos, 
viktförändring efter diagnos och fysisk aktivitet efter diagnos påverkade prostatacancerspecifik 
dödlighet (död orsakad av cancern) och total dödlighet. BMI används ofta för att definiera vad som 
är normalvikt (BMI <25kg/m
2
), övervikt (BMI 25<30kg/m
2
) eller fetma (BMI >30kg/m
2
). Vi fann 
inget samband mellan BMI och progression eller prostatacancerspecifik dödlighet. Däremot hade 
män med ett BMI över 30 kg/m
2
 högre total dödlighet jämfört med normalviktiga män. Detta kan 
bero på den ökade risken för hjärt- och kärlsjukdom som är förknippad med ett högt BMI. När vi 
studerade viktförändring fann vi att män som ökade mycket i vikt efter diagnos hade högre 
prostatacancerspecifik dödlighet jämfört med män som höll en stabil vikt. Män som istället gick 
ner mycket i vikt hade högre total dödlighet. Detta kan delvis förklaras med att sjukdomen i sig kan 
leda till både viktnedgång och dödlighet. Det är alltså inte viktnedgången i sig som ökar 
dödligheten utan en mer svårartad sjukdom. Samantaget visar våra resultat att det efter en 
prostatcancerdiagnos kan vara till fördel att undvika viktuppgång och att ett högt BMI kan öka 
risken att dö i förtid.  
 
I den andra delstudien (II) undersökte vi kopplingen mellan olika typer av fysisk aktivitet och 
dödlighet. Män som rapporterat att de promenerade eller cyklade mer än 20 minuter per dag eller 
utförde mer än 1 timmes hushållsarbete per dag eller tränade mer än 1 timme i veckan hade lägre 
total dödlighet jämfört med män som rapporterat att de utförde aktiviteterna mer sällan eller under 
kortare tid. Vi såg också en minskad dödlighet från prostatacancer hos de män som rapporterat att 
de promenerade eller cyklade mer än 20 minuter per dag eller tränade mer än 1 timme i veckan. 
 Våra resultat är bland de första i världen att visa på positiva effekter av fysisk aktivitet på både 
prostatacancerspecifik och total överlevnad och att en aktiv livsstil kan förlänga livet efter en 
prostatacancerdiagnos. 
 
I delstudie fem (V) undersökte vi sambandet mellan BMI och prostatacancerrisk samt kopplingen 
mellan BMI och PSA i blod. Våra resultat visade inte på något samband mellan BMI och risken för 
prostatacancer men vi såg att män med högre BMI hade lägre PSA-koncentrationer. Eftersom PSA 
används för att tidigt upptäcka prostatacancer är det viktigt att veta vilka faktorer som kan påverka 
koncentrationen av PSA och därmed tolkningen av provresultat.  
 
I avhandlingens andra del (delstudie III och IV) undersökte vi validiteten och reproducerbarheten 
hos den webbaserade enkäten Active-Q. I delstudie tre (III) studerade vi hur väl Active-Q mätte 
total energiförbrukning och fysisk aktivitet hos vuxna. Energiförbrukning skattad med enkäten 
jämfördes mot resultat från dubbelmärkt vatten (DLW). DLW är en biomarkör och den bästa 
metod som finns tillgänglig för att mäta total energiförbrukning. Vi utvärderade också hur bra 
enkäten var på att skatta den totala aktivitetsnivån genom att jämföra resultat mot totalt antal 
dagliga steg. I delstudie fyra (IV) utvärderade vi hur väl Active-Q skattade tid spenderad på olika 
aktivitetsnivåer (stillasittande, måttlig och hög nivå) jämfört med accelerometermätningar. En 
accelerometer mäter acceleration, det vill säga rörelse, mycket noggrant. 
 
I delstudie tre (III) visade Active-Q medelgod validitet med avseende på total energiförbrukning. I 
genomsnitt överskattade enkäten den totala energiförbrukningen något. Jämförelsen mellan total 
aktivitetsnivå och dagliga steg visade på låg överenstämmelse mellan metoderna. Detta kan dock 
bero på att det totala antalet steg per dag inte är ett bra mått på total aktivitet. I delstudie fyra (IV) 
visade jämförelser av tid spenderad på olika aktivitetsnivåer på medelgod validitet när resultat från 
Active-Q jämfördes med accelerometermätningar. Enkäten överskattade tid spenderade på måttlig 
och hög aktivitetsnivå medan stillasittande underskattades. Reproducerbarheten av upprepade 
skattningar med enkäten var god i båda studierna. Sammantaget visar våra resultat på god validitet 
hos Active-Q för mätningar av total energiförbrukning och tid spenderad på olika aktivitetsnivåer. 
 
Resultaten i denna avhandling bidrar med ny kunskap om hur BMI, viktförändring och fysisk 
aktivitet är kopplat till prostatacancer. Vi visar även att BMI påverkar koncentrationen av PSA i 
blodet. BMI bör därför vägas in i tolkningen av PSA vid diagnosticering av prostatacancer. Med 
tanke på de 85000 män som idag har eller har haft prostatacancer är våra resultat mycket lovande 
och erbjuder möjligheter för män att själva välja en aktiv livsstil som inte bara har positiva effekter 
på den allmänna hälsan utan också förbättrar överlevnaden efter en prostatacancerdiagnos. Vi visar 
också att den webbaserade enkäten Active-Q kan användas i framtida studier för att mäta fysisk 
aktivitet. 
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1 INTRODUCTION 
 
“Walking is man's best medicine”  
Hippocrates c. 460 - 377 B.C. 
 
 
Already in ancient Greece, physical activity was known to have positive effects on 
health. However, even with more knowledge than ever before, we are adopting more 
and more sedentary lifestyles and have never been less active than we are today. 
Physical inactivity has been identified as the fourth leading risk factor for global 
mortality by the World Health Organization (WHO).
2
 
 
Concomitant to being increasingly inactive, or perhaps because of, the number of 
overweight or obese individuals worldwide has increased dramatically during the past 
decades.
3
 Nevertheless, overweight and obesity are preventable and as physical 
inactivity, modifiable. This gives us great possibilities to influence our own health by 
changing our lifestyle. It is also important to remember that other lifestyle factors, 
including for example diet, plays an important role in our health. Physical activity 
contributes to our energy expenditure (energy output) and diet contributes to our energy 
intake (energy input). Our body weight represents the result of the balance between 
output and input and reflects our energy storage. While all factors in this triad are 
important for our health, this thesis will focus on body weight and physical activity. 
 
To better understand what a healthy weight and a sufficient level of activity are, we can 
study the associations between these behaviors and different health outcomes in 
epidemiological studies. Our results may guide policy makers and prevention strategies 
for different outcomes of specific interest. However, assessing physical activity is not 
trivial. Most large epidemiological studies rely on self-reported questionnaires to assess 
this complex behavior as this is a cost-efficient method with a low participant burden. 
To make sure that you are actually measuring what you think you are measuring, it is 
important to use a validated questionnaire.  
 
Prostate cancer is the second most common cancer in men globally and the most 
common among men in developed countries.
4
 What causes or may prevent the disease 
is still unclear but lifestyle factors, including body weight and physical activity, may be 
of importance for both the development and progression of tumors. Finding ways to 
reduce the incidence and mortality of prostate cancer is of great public health concern. 
As overweight and obesity and physical activity or inactivity are modifiable factors, 
they are of particular interest to study in relation to the disease.  
 
This thesis has two parts. The first part concerns how body weight and physical activity 
affects progression of tumors and survival after prostate cancer diagnosis (Study I and 
II) as well as levels of prostate specific antigen (PSA) and the risk of developing 
prostate cancer (Study V). The second, more methodological part, concerns the 
development and validation of a new web-based physical activity questionnaire, 
Active-Q, designed for use in large epidemiological studies (Study III and IV). 
 2 
2 BACKGROUND 
 
2.1 EPIDEMIOLOGY 
In epidemiology, we study the causes and spread of health and disease in a population. 
With the aim of drawing conclusions regarding the causality of associations between 
different exposures and outcomes we develop methods for better assessment of such, 
keep detailed registries, design our studies and model our data as best we can. 
However, although we aim to find out how the real world works, we can only study 
what we are able to observe and measure. While descriptive epidemiology will give us 
information regarding the occurrence of an outcome in the population, the associations 
between exposures and outcomes are described using analytical epidemiology where 
information from observational or experimental studies is analyzed. To make 
interpretations with a public health implication, information from both descriptive and 
analytical studies are needed. Even if there is a strong association between a risk factor 
and an outcome, the implications on public health may be small if the occurrence of the 
exposure or outcome is rare. 
 
2.1.1.1 Epidemiological study design 
The three association studies (Study I, II and V) included in this thesis are based on 
data from two cohort studies. A cohort is a group of people at risk for the outcome of 
interest, i.e. not having experienced the outcome at the start of the cohort, followed 
over a specific amount of time. During the follow-up time, outcome events and 
exposures are assessed either prospectively or retrospectively. The incidence of the 
outcome is then compared among the exposed and unexposed to determine if it differs 
between the two groups. Cohort studies are useful when studying common outcomes or 
multiple outcomes or exposures. When studying a rare outcome, a case-control design 
may be more efficient and worth mentioning although this type of design is not 
included within this thesis work. In a case-control study, cases (individuals having 
developed the outcome) and controls (individuals that have not developed the outcome) 
are sampled from a source population (which can be thought of as a cohort). The 
exposure status is thereafter assessed among cases and controls. Results from 
association studies may guide intervention studies and clinical trials where exposure 
(or no exposure) is assigned to individuals who are thereafter followed-up. A 
randomized trial is a study where the exposure is randomly assigned to participants, a 
study design that aims to remove the influence of confounding from other factors by 
creating an equal distribution of such factors among both exposed and unexposed 
individuals.  
 
2.1.1.2 Confounding  
Confounding is caused by a third factor affecting the association between an exposure 
and an outcome. If confounding is present and not controlled for, the observed 
association may be biased. This can lead us to see associations where there are no or to 
true associations being masked. A confounder is a factor that is associated with and 
causes both the exposure and the outcome. Confounding can be addressed directly in 
the study design (e.g. by randomization or matching) or at the analysis stage, by 
controlling for known and measured confounders in statistical models. Even if 
confounding is controlled for to the best of our ability, there may always be unknown, 
unmeasured or residual confounding affecting the results. Other factors which are 
   3 
associated with both the exposure and outcome but that are not confounders are 
mediators and colliders. A mediator is a factor that lies in the causal pathway between 
an exposure and an outcome, i.e. it is an effect of the exposure and a cause of the 
outcome. A collider is an effect of both the exposure and the outcome. Controlling for 
mediators and colliders may cause bias similar to not controlling for confounders. 
Directed Acyclical Graphs
5
 can be used to visually display associations between an 
exposure and an outcome and other factors affecting the association, Figure 1.  
 
 
 
 
2.1.1.3 E-epidemiology 
Using the Internet for epidemiological research (e-epidemiology) has during the recent 
decade changed the prerequisites for large scale data collection.
6
 The use of web-based 
questionnaires to collect data is more rapid and cost effective than traditional modes of 
data collection, including use of paper-based questionnaires, and offers additional 
advantages such as increased data quality due to implementation of automatic checks 
for errors or missing answers.
7
 Internet access in Sweden is high, with more than 90% 
of all adults having access at home.
8
 The validity of web-based self-reports of lifestyle 
factors is generally reported to be high.
7
 The newly developed web-based physical 
activity questionnaire Active-Q is validated in Study III and IV in this thesis and used 
in the large scale data collection in Study V. 
 
 
2.2 BODY MASS INDEX 
Our body weight reflects our body’s storage of energy which is a result of the balance 
between the energy intake from the food we eat and our energy expenditure from being 
alive, breathing, digesting food and being physically active. An imbalance between the 
intake and the expenditure will lead to weight loss if the intake is less than the 
expenditure and a weight gain if the intake is greater than the expenditure. Our body 
weight, however, also depends on other factors including our height and body 
composition (e.g. muscle mass, bone mass, fat mass and total body water).  
 
Body mass index (BMI) is used in most large epidemiological studies as a proxy 
measure for body fat as it is easy to assess in large study populations. Other methods 
for assessing body composition in detail include bioelectrical impedance analysis, dual 
energy x-ray absorptiometry, and dilution techniques, among others.
9
 BMI is body 
weight in kilograms divided by height in meters squared (kg/m
2
). Adults with a BMI 
<18.5, 18.5<25, 25<30 and ≥30 kg/m2 are usually defined as being underweight, 
normal weight, overweight or obese, respectively.
10
 However, the fact that BMI does 
not differentiate between fat free mass and fat mass is a major limitation and subjects 
with high muscle mass and low fat mass may be incorrectly classified as overweight or 
obese by BMI.
11, 12
  Nevertheless, BMI has been shown to perform similar to waist 
circumference as an indicator of body fat.
13
 
 
Figure 1. Example of a Directed Acyclic 
Graph (DAG) illustrating the relationship 
between an exposure and an outcome. 
The arrows indicate associations and the 
direction of such 
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There is a clear trend between a high BMI and negative health consequences including 
increased risk of mortality from hypertension, dyslipidemia, type-2-diabetes, coronary 
heart disease and some types of cancer as well as overall-mortality.
10
 The prevalence of 
overweight has increased dramatically during the last decades and the prevalence of 
obesity has nearly doubled since1980.
14
 In 2014, 49% of all adult men in the world and 
57% of men ages 16-84 years in Sweden were overweight or obese.
14, 15
 The prevalence 
was even higher among Swedish men in the age groups 45-64 and 65-84 years, where 
69 and 67%, respectively, were overweight or obese, respectively. The high and 
increasing prevalence of overweight and obesity makes it important to determine any 
potential effects a high BMI may have on our health.  
 
 
2.3 PHYSICAL ACTIVITY 
Physical activity is a multidimensional behavior defined as “Any bodily movement 
produced by skeletal muscles resulting in energy expenditure”.1 According to this 
definition, any activity, however sedentary, light, moderate or vigorous, as long as it 
results in contractions of skeletal muscles producing energy expenditure, is physical 
activity. Nevertheless, many of us think about exercise when we hear physical activity, 
but to be clear, exercise has been defined as “Physical activity that is planned, 
structured and repetitive, and results in the improvement or maintenance of one or more 
facets of physical fitness”.1 Physical fitness is in turn the resulting physical outcome 
from being physically active or exercising and has been defined as “A set of out-comes 
or traits that relate to the ability to perform physical activity”.1 The relationships 
between the different physical activity behaviors are shown in Figure 2. 
 
Our physical activity behavior is closely related to our total energy expenditure which 
is composed of three main parts. The most modifiable part is the result of our physical 
activity and is dependent on the frequency, duration and intensity of the physical 
activities we perform. This part can vary greatly between individuals but is usually in 
the range of 15-30% of our total energy expenditure, although both lower and higher 
percentages may occur in very sedentary and very active individuals respectively. The 
largest part of our total energy expenditure, approximately 60-75%, is our basal 
metabolic rate (BMR), i.e. the energy we need to expend to stay alive.
16
 BMR is a 
function of body size and body composition, which are mainly affected by sex, age, 
weight and height, as well as other factors including physical fitness and explains much 
of the variation seen in total energy expenditure between subjects. Standard equations 
for estimating BMR take sex, age, weight and height into account.
17
 Lastly, an 
additional 10% of our total energy expenditure is the energy we need to digest food and 
absorb nutrients, i.e. diet induced thermogenesis. Our body weight is stable when our 
total energy expenditure and our energy intake are in balance. Figure 2 describes the 
relationship between components of our total physical activity behavior and energy 
expenditure. Our total energy expenditure can also be expressed as multiples of BMR. 
The resulting physical activity (PAL) value is comparable between individuals as it by 
definition controls for factors which influence BMR, i.e. sex, age, weight and height. 
 
Physical activity epidemiology can be divided into a two part process.
18
 In the first part, 
the association between physical activity behavior and disease or health outcomes, 
potential determinants for the physical activity behavior and possible interrelationships 
between physical activity and other behaviors are studied.  Secondly, the knowledge 
gained in the first part is applied to health promotion and prevention and control of 
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disease.
18
 However, the process is dependent on valid and reproducible methods for 
assessing physical activity. 
 
 
 
 
 
2.3.1.1 The concept of metabolic equivalents (METs) 
An important concept within physical activity research is metabolic equivalents (MET), 
a multiple of BMR representing the intensity of a specific activity.
19
 For example, an 
activity with a MET=1 (e.g. lying down or sitting quietly), does not increase the energy 
expenditure at all compared to our BMR (BMR*1) whereas an activity with a MET=3 
(e.g. walking), raises our energy expenditure by three times (BMR*3) during the time 
of performing the activity. The higher the MET, the more intense the activity and the 
more energy is expended during performance. BMR in a healthy, normal weight adults 
can be approximated to equal an energy expenditure of 1 kcal·kg
-1
 body weight·h
-1
. 
This corresponds to an oxygen consumption of 3.5 ml O2·kg
-1
 body weight·minute
-1
. 
Performing an activity with an intensity of 3 MET will therefore result in an energy 
expenditure of 3*1 kcal·kg
-1
 body weight·h
-1
, i.e. the total energy expended depends on 
the individuals body weight and the duration of the performed activity. Examples of 
using MET-values to calculate the energy expenditure during four different activities 
are shown in Table 1. 
 
Table 1. Examples of the energy expenditure for one individual having a body weight of 60 kg when 
performing activities with different MET-values for 1 hour.  
 
 Activity MET-value
1
 Activity level Calculation 
MET ·kg
-1
 body weight·h
-1
 
Estimated Energy 
Expenditure (kcal) 
 Sitting 1.0 Sedentary 1.0 (MET) · 60kg · 1 h 60 
 Standing 2.5 Light 2.5 (MET) · 60kg · 1 h 150 
 Walking 3.0 Moderate 3.0 (MET) · 60kg · 1 h 180 
 Running 7.0 Vigorous 7.0 (MET) · 60kg · 1 h 420 
1
Ainsworth et al. 2011 Compendium of Physical Activities: A Second Update of Codes and METvalues 
Figure 2. Constitutes and definitions of physical activity behavior
1
 and the relationship to total 
energy expenditure of which the physical activity energy expenditure is modifiable. 
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Activities are often categorized by intensity as sedentary (MET <1.5), light (MET 
1.5<3), moderate (MET 3<6) or vigorous (MET >6) depending on the MET-value for 
each activity. Ainsworth et al.
19-21
 has published comprehensive lists of MET-values for 
various activities. Although the use of METs to estimate individuals’ energy 
expenditure from, for example, physical activity questionnaires is widespread, it is not 
without limitations. Factors including age, sex, body weight and body composition, as 
well as physical fitness affect the energy cost of activities.
22, 23
 The underlying 
assumptions for MET-values in adults do not hold for all individuals. In for example 
obese persons, the oxygen consumption per kg-body weight may be lower than that of 
normal weight persons.  
 
2.3.1.2 Physical inactivity 
For a long time, epidemiological research has been focused on physical activity but 
more recently, attention has been given to our increasingly sedentary behaviors and 
inactivity. Together with light intensity activities, sedentary time comprises most of our 
daily activity. Sedentary behaviors are usually defined by a posture of sitting or lying 
down and their low energy expenditure corresponding to a MET-value below 1.5. 
During the past decades, declines in work-related activity and active transportation 
have led to the accumulation of increased amounts of sedentary time.
24
 In Sweden, time 
spent sedentary has increased by almost half-an-hour per day in only six years between 
2002 and 2008.
25
 Now recognized as an important lifestyle factor, sedentary behavior 
has been suggested as an independent risk factor for both metabolic diseases and all-
cause mortality
26, 27
, and WHO has listed inactivity as the fourth leading risk factor for 
mortality worldwide.
28
 When talking about physical activity and the benefits of being 
active, we also need to remember the negative impact that inactivity has on our health.  
 
2.3.1.3 Physical activity recommendations 
To maintain health, Swedish adults are recommended to engage in at least 150 min per 
week of activity on a moderate level or 75 min per week on a vigorous level.
29
 
Activities should be performed in bouts of 10 min and to achieve additional health 
benefits the amount of activity should be increased. The newest addition to the Nordic 
recommendations on physical activity is an additional point encouraging sedentary time 
to be decreased.
29
 Similar recommendations are issued by the American College of 
Sports Medicine and the American Heart Association
30
, as well as by the WHO.
2
 
 
 
2.3.2 Measuring physical activity  
Accurate exposure assessment is critical in epidemiological studies of for example 
physical activity. Valid and reliable methods for measuring this complex behavior are 
therefore a key issue when aiming to study the associations between physical activity 
and any outcome. There are many different methods available today and the choice of a 
method for any specific study should be considered carefully. Both scientific as well as 
logistic considerations need to be made depending on the dimension of the physical 
activity of interest and the type of study conducted. While research has had to rely on 
self-reported measures such as questionnaires in the past, the development of new 
technologies, such as accelerometers, has made it possible to measure physical activity 
objectively in large-scale studies as well. Common methods of physical activity 
assessment in adults used in epidemiological studies are summarized in Figure 3. 
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2.3.3 Self-reported methods 
Much of what we know today regarding associations between physical activity and 
different health outcomes is based on self-reported measures of physical activity which 
have been used in research during the past century.
31
 The most common methods for 
collecting self-reported physical activity data are through questionnaires or by 
diaries/records. Although self-reported instruments are widely used, they are not 
without limitations such as social desirability bias, cognitive demands on recall and 
difficulties capturing all physical activities performed.
32
 Central to this thesis work are 
physical activity questionnaires. 
 
2.3.3.1 Physical activity questionnaires 
Self-reported physical activity questionnaires are cost effective and convenient to use. 
They generate both quantitative (frequency and duration) and qualitative (settings and 
domains of activity) information, the latter is not captured by objective methods. 
However, we must not forget the limitations of physical activity questionnaires which 
are prone to bias and measurement errors, which need to be addressed.
32, 33
 A limited 
number of included activities and pre-defined response intervals may have an effect on 
the results and must be carefully considered at the design stage of a questionnaire. 
Physical activity is many times over-estimated while time spent sedentary is under-
estimated .
34
 Intentional or unintentional misreporting may differ between subgroups. 
Women have been seen to over-report more than men, and a high BMI has also been 
associated with high levels of self-reported physical activity when compared to direct 
measures.
34, 35
     
 
It is important to assess validity and reliability of any questionnaire within the specific 
population in which it is intended to be used. The time frame that the questionnaire 
aims to measure, the types of activities included, the length of the questionnaire, and 
frequencies used for assessment of activities must also be carefully considered. These 
factors are important for the questionnaire’s performance and interpretation of the 
Figure 3. An overview of commonly used methods to assess physical activity among adults in 
epidemiological studies 
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results.
33
 Structured questionnaires can provide information on physical activity within 
different domains as well as the frequency and duration of different activities.   
 
There are many different physical activity questionnaires available and even more 
validation studies published. These have been summarized in several extensive 
reviews.
36-38
 Physical activity questionnaires have previously been focused on activity 
and usually capture recreational activities and activities performed during leisure time. 
Today most questionnaires also assess physical activity within additional domains, such 
as occupation and the majority of newly developed questionnaires also include 
sedentary activities. The time frame measured in a questionnaire can vary from a period 
of one day to the past months or year. A very common time frame is the “last 7 days” 
or during “a typical week”.36 Over-reporting of physical activity is common due to 
misreporting of frequency, intensity and/or duration of activities and can be caused by 
for example social desirability and memory bias.
39
 In particular older individuals may 
have cognitive difficulties in recalling activities.
40
 
 
In an extensive review by Helmerhorst et al.
36
, most physical activity questionnaires 
reported a good to high reliability but poor to moderate validity. While the absolute 
validity was limited, the questionnaires appeared valid for ranking subjects. Sedentary 
behavior was reportedly a difficult domain of activity to measure and correlations with 
objective measures were poor. However, as the authors argue, objective methods 
themselves are limited in measuring sedentary behavior, which may contribute to 
poorer agreement. Interestingly, despite the many new questionnaires being developed, 
no substantial difference was seen between newer and already existing questionnaires.
36
 
In an attempt to develop a standardized questionnaire assessing overall physical 
activity, the international physical activity questionnaire (IPAQ)
41
 and the global 
physical activity questionnaire (GPAQ)
42
 assessing physical activity during the past 
seven days have been developed.  
 
 
2.3.4 Objective methods 
Technology development during the past decades has added to the field of physical 
activity research and although still more expensive, new objective methods are much 
more available and feasible to use in large-scale studies today than ever before. 
Objective methods include doubly labelled water (DLW), accelerometers (motion 
sensors), pedometers and heart rate monitors. While good at capturing the overall 
physical activity measured as energy expenditure, acceleration, steps or heart rate, these 
objective methods do not capture qualitative information regarding activities performed 
or the context in which they were performed.
43
 Central to this thesis work is the DLW-
method and accelerometers.  
 
2.3.4.1 Doubly labeled water (DLW) 
To assess total energy expenditure, the DLW-method was used as the criterion 
measure.
16
 The method utilizes the stable isotopes deuterium (
2
H) and 18-Oxygen (
18
O) 
and DLW is a mixture of the stable isotope labelled waters 
2
H2O and H2
18
O. The DLW 
equilibrates with the human body’s water pool and uses the kinetics of the water 
turnover in the body to estimate the rate of carbon dioxide (CO2) production, i.e. it does 
not measure respiratory gases directly. The isotope marked water molecules will 
distribute in the body water compartment and although water molecules are leaving our 
body as vapor or part of urinary, fecal or other fluids constantly, the body water pool is 
relatively stable in size as the input and output of water is generally the same.  
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To assess total energy expenditure, the elimination kinetics of the two stable isotopes 
are measured in urine using gas isotope ratio mass spectrometry.
16
 The decline in 
2
H is 
a function of the H2O-turnover in the body while the decline in 
18
O is a function of both 
the H2O-turnover and CO2-production. Since the oxygen in our body water and 
respiratory CO2 are in equilibrium, the difference between 
2
H and 
18
O water turnover 
curves is 
18
O lost from CO2, Figure 4. The difference is integrated over a specified 
measurement period to determine total CO2 production. Thereafter, the total energy 
expenditure can be calculated through standard equations
44
 using an appropriate 
respiratory quotient (RQ) for the specific population. The RQ is the ratio between the 
CO2 produced and the O2 consumed and depends on our dietary composition as 
different macronutrients have different RQs. 
 
 
 
Important to note is that in calculations of CO2, corrections are made for isotopic 
exchange and fractioning. Further, the DLW technique relies heavily on four major 
assumptions; 1) that the body water pool is a steady state, single compartment pool 
with complete and rapid equilibration, 2) that the isotopes exit the body as only CO2 or 
water, 3) that isotopes exit the body only while in isotopic equilibrium with body water, 
and 4) that the CO2 and water lost from the body do not re-enter the body water pool.
16
 
The assumptions are generally robust. 
 
2.3.4.2 Pedometers 
Using pedometers to measure daily steps is an easy and inexpensive method to assess 
overall physical activity. While older pedometers were mechanical, newer versions are 
more often electronic. Pedometers are specifically designed to assess walking and will 
measure the number of steps taken during a defined time period. Reviews on pedometer 
methodology reach similar conclusions stating that it is a good overall method for total 
physical activity represented by step counts, but that it lacks the ability to assess 
intensity, frequency and duration of movement or energy expenditure.
45-48
 While 
pedometer output has been strongly correlated with results from accelerometer 
measurements and direct observation, correlations with energy expenditure and self-
reported physical activity have been moderate.
49
 The highest accuracy in pedometer 
output has been found for step counts, less accurate results were seen for estimations of 
energy expenditure.
50
 A wide variety in the precision of pedometer measurements has 
also been seen and while some pedometers measured steps within 3% of actual values, 
others had a larger variety of ±37%.
51
 Due to variability in for example mechanisms 
and validity, the output of different pedometers is not comparable.  
 
The number of days of pedometer wear required for a valid estimation of physical 
activity levels depends on a number of things. For example the specific research 
question, if the aim is to assess habitual physical activity or a snap-shot of the current 
activity level. Other factors include the characteristics of the study population and the 
available resources. However, the within-individual variability due to real life-
Figure 4. Graph exemplifying the 
elimination of 
2
H and 
18
O through 
water turnover and the resulting 
difference representing the 
18
O 
lost from CO2.  
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fluctuations decreases when the number of days measured increases.
52
 Reactivity, i.e. 
changes in activity behavior caused by measurement of the behavior, among study 
participants wearing pedometers has been seen in several studies
53-55
 but not all.
56
 
Under certain conditions there is reactivity to pedometer wear and participants who are 
able to view steps and instructed to log them may increase their daily steps by as much 
as 15 % during the time of monitoring .
47
 Only viewing the steps causes less reactivity 
while use of sealed pedometers has little or no reactivity effect at all.
47
 
 
2.3.4.3 Accelerometers (motion sensors) 
Rapid development of accelerometer technology has led to many different monitors 
being available and has opened up for widespread use. Most accelerometers are small 
and easily wearable instruments that register acceleration on one or more planes. 
Information regarding the frequency, duration and intensity of an individual’s physical 
activity can be indicated from accelerometer measurements
45
, while qualitative and 
contextual information is not obtained. Many accelerometers today are tri-axial, i.e. 
they register acceleration in three planes, with sampling rates typically in the range of 
40 to 100 Hertz (Hz). The large amount of information captured is usually comprised 
into epochs of lower resolution. Similar to data on pedometer wear, the number of 
measured days needed may differ. To assess habitual physical activity in adult 
populations, 3-5 days is likely to be sufficient.
57
 Since habitual activity may differ 
between weekdays and weekend days, the wear period should include both. Few 
studies have assessed reactivity to accelerometer wear but their similarities to sealed 
pedometers indicate that the effects most likely are minor. 
 
Results from accelerometer measurements are often referred to as counts due to the 
dimensionless nature of the data. Moderate-to-strong correlations have been seen 
between accelerometer counts and different physical activity measures such as oxygen 
consumption, physical activity energy expenditure and MET-hours.
57
 A challenge for 
researchers is to define the counts and translate, or calibrate, the results into variables of 
for example energy expenditure or time spent at different intensity levels.
58
 This is 
often done by performing a calibration study where accelerometer counts are compared 
to oxygen consumption during performance of pre-defined activities. Thereafter, cut-
offs to classify the accelerometer output into categories of intensity or transform it into 
energy expenditure are developed based on the measured oxygen consumption. Pre-
defined MET-values of performed activities may be used instead of measured oxygen 
consumption although they give less precise estimates. However, inconsistency 
between methods used in calibration studies has led to difficulties in comparing results 
from different studies and types of accelerometers.
59
 While accelerometers capture both 
sedentary behaviors and higher intensities of physical activity, the sensitivity of 
measurements is poor in the lower range of activities and most non-ambulatory 
activities, e.g. bicycling and weight lifting, are not measured correctly.
45
  
 
 
2.4 PROSTATE CANCER  
2.4.1 The prostate 
The prostate is a walnut sized gland, located just below the urinary bladder and in front 
of the rectum. It surrounds the upper part of the urethra and is surrounded by nerves 
controlling erection. The prostate is part of the male reproductive system and the main 
function is to produce fluid which protects and enriches sperm cells. The prostate starts 
to develop before birth, but typically grows during adolescence under regulation of the 
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male hormone testosterone and its byproduct dihydrotestosterone, and reaches full size 
around age 20. Among men older than 50 years, the prostate is commonly enlarged in a 
benign manner (benign prostatic hyperplasia). This usually harmless condition can in 
some cases cause problems with urination but is not related to prostate cancer. 
 
 
2.4.2 Disease description 
Prostate cancer is the most common cancer among Swedish men.
60
 While it is very 
common in older ages it is very rare among men younger than 40 years. Almost all 
(90%) prostate cancers are adenocarcinomas and arise in the gland cells of the prostate. 
The remaining, rarer, types of prostate cancer arise from other types of cells. Early 
stage prostate cancer will most likely not cause any symptoms and can therefore be 
hard to detect. Early symptoms of prostate cancer may include frequent urination, 
difficulty maintaining a steady stream of urine, problems with erection and ejaculation, 
and blood in the urine. Late symptoms, often arising when the cancer has spread, 
include pain in the back or hips as a results of the cancer having metastasized. Weight 
loss and fatigue are also common symptoms for most cancers at a late stage. 
 
Most prostate cancers are very slow growing and can remain asymptomatic for years 
from tumor initiation and some men will never experience any symptoms. In reality, 
many men, whether diagnosed or not, will live the rest of their lives without any 
symptoms of the prostate cancer and are likely to die from something unrelated to the 
cancer, such as cardiovascular disease. Nevertheless, there are more aggressive tumors 
that may metastasize to the bone or lymph nodes and cause premature death.  
 
Although some prostate cancers are found after the patient has experienced symptoms, 
most cancer are asymptomatic and are detected as a result of a blood test showing 
elevated levels of prostate-specific antigen (PSA). A PSA-test indicating a possible 
tumor is followed-up by a physician examination and biopsies to confirm diagnosis. At 
the time of diagnosis it is important to determine if the tumor is likely to be aggressive 
or to grow more slowly having a better prognosis. Together with age, general health 
and other symptoms, the tumor grade and stage will guide treatment options. While 
more aggressive tumors of higher grade and stage may be treated using surgery, 
radiation therapy, hormone therapy, chemotherapy or other alternatives, patients with a 
slow growing early tumor can be followed-up with active surveillance where the tumor 
is monitored closely by a physician and regular checks of any potential tumor 
development are made. 
 
 
2.4.3 Incidence and mortality 
Prostate cancer is the second most common cancer in the world today and over 1 
million men were diagnosed in 2012.
61
 However, the incidence rates vary largely 
between different regions in the world with Australia, New Zealand, North America, 
and northern and western Europe having the highest rates, sometimes as high as 25 
times the rate of some parts of Africa and Asia. Almost 70% of the total number of 
diagnosed men lives in the more developed regions of the world. From the mid 1980’s 
to today, the incidence of prostate cancer has increased worldwide.
62
 While there was a 
steep increase in the incidence of prostate cancer in Sweden during the late 1990’s, 
rates have stabilized and even decreased slightly during recent years
62
, see Figure 5. 
The introduction of the prostate-specific antigen (PSA) test during the late 1990’s most 
likely explains the steep increase during this time period. The age-standardized 
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incidence rate in Sweden is approximately 100 per 100,000 men and around 9,600 men 
were diagnosed with the disease yearly between 2007 and 2011.
60
  
 
The relative survival among men in Sweden with prostate cancer is good. The 5-year 
survival is over 90% and the 10-year survival just above 80%.
63
 Nevertheless, around 
2,400 Swedish men die as a result of their prostate cancer every year. The high 
incidence and relatively low mortality, see Figure 5 for trends during the past decades, 
has resulted in a large number of living men having been diagnosed with prostate 
cancer. The prevalence of men that have ever been diagnosed (regardless of time since 
diagnosis or if the cancer is considered cured) in Sweden is almost 85,000.
60
 
 
 
 
 
2.4.4 Prostate Specific Antigen (PSA) 
One possible explanation for the relatively steep increases in prostate cancer 
incidence in the late 1980’s and 1990’s is the introduction of the PSA-test.62 PSA is 
an enzyme naturally present in low levels in the serum of healthy men. PSA-levels 
increase naturally with age but elevated levels may be a sign of disease such as 
prostate cancer, benign prostatic hyperplasia or inflammation. The intensity of testing 
varies around the world and may explain differences in incidence between countries. 
When the PSA-test was introduced, the rationale was to increase early detection of 
prostate cancers and reduce mortality from the disease. However, the test has led to 
increased numbers of men being diagnosed at lower PSA-levels and at younger 
ages.
64
 Many men are therefore diagnosed even though the tumor might be slow 
growing and may never result in physical symptoms. The risk of over-diagnosis is 
another downside of the PSA-test. It has been estimated that 23-42% of cancers 
detected using the PSA-test are over-diagnosed and would never have caused any 
clinical problems.
65
 The psychological burden of having been diagnosed with prostate 
cancer is sometimes greater than the physical burden of the disease itself. Adding to 
the controversy is that lack of evidence showing that PSA-testing reduces prostate 
cancer mortality.
64
  
 
Sweden does not have a general screening program for prostate cancer. The National 
Board of Health and Welfare did an extensive review of the scientific literature and 
decided against it in 2013.
66
 The decision was made based on the fact that the 
negative effects of a screening program, e.g. over-diagnosing and overtreatment, 
would exceed a potential increase in survival. Had a screening program for prostate 
Figure 5. Prostate cancer 
incidence and mortality in 
Sweden between the 
years 1952 to 2012.  
 
       Incidence 
       Mortality 
 
 
 
Source: NORDCAN © 
Association of the Nordic 
Cancer Registries (Generated 
and downloaded 29.8.2014) 
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cancer been introduced, the mortality was estimated to decrease by 1 to 4 men per 
1000 men after 10-15 years while 40-50 more men would be diagnosed with prostate 
cancer each year then if there were no screening program.  An increased number of 
men with small, slowly growing tumors would be treated and thereby be at risk for 
potential side effects of treatment. Despite the lack of a national screening program, 
PSA-testing is common in Sweden and has increased during the past decade.
67
 More 
than 65% of men without a previous prostate cancer diagnosis aged 60-69 years had a 
PSA-test in 2011. 
 
 
2.5 PROSTATE CANCER EPIDEMIOLOGY 
2.5.1 Body mass index and prostate cancer  
Co-occurring with the increasing prostate cancer incidence today is the increasing 
prevalence of overweight and obesity. In Sweden, over 65% of men 45 years of age 
or older were overweight or obese in 2014.
15
 Overweight, obesity, and prostate cancer 
affect substantial proportions of the male population but few specific risk 
determinants for prostate cancer have been identified to date. Body weight is of great 
interest to study as it is a modifiable lifestyle factor with the potential to influence the 
risk and development of prostate cancer. 
 
Body weight is related to both metabolic and hormonal pathways, an example is fat 
mass which plays an important role in hormone metabolism.
68
 Since prostate cancer 
is hormone related it is likely to be linked to anthropometric factors. Although 
previous studies suggest a possible association between BMI and the risk of prostate 
cancer, results are inconsistent and the relationship appears complex.
69
 While 
previous studies have shown no association between BMI and the overall risk of 
prostate cancer or risk of low-grade cancer, a high BMI has been positively associated 
with aggressive or fatal prostate cancer.
70-73
 More recently, a dual effect of obesity on 
prostate cancer risk has been suggested. A meta-analysis showed an increased risk of 
more advanced or aggressive disease and a decreased risk of early stage and less 
aggressive cancers with increasing BMI.
74
. A possible explanation for the association 
between BMI and risk of different prostate cancer subtypes is the fact that higher 
BMI has been associated with lower serum PSA concentrations
75
, potentially leading 
to later detection of tumors. Indeed, plasma hemodilution yielding lower PSA values 
may be one explanation for delayed diagnosis and therefore poorer prognosis.
76
 
 
The more consistent association between high BMI and increased risk of aggressive 
prostate cancer suggest that BMI might be of greater importance for the progression 
of prostate tumors rather than for tumor development.
77
 A high BMI has been 
associated with an increased risk of both progression and prostate cancer specific 
mortality.
78
 The association with prostate cancer specific mortality has recently been 
shown to be even more pronounced in men with more aggressive disease.
79
  
 
 
2.5.2 Body mass index and PSA-levels 
A possible explanation for the association between overweight and obesity and prostate 
cancer risk might be an effect of a high BMI on serum PSA-levels.  Numerous studies 
have established an inverse association between BMI and PSA-levels.
75, 76, 80-86
 An 
increased BMI may lead to decreased serum PSA-levels through mechanisms of; 
decreased testosterone levels
87
, hemodilution
76
 or a larger prostate size making it harder 
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to biopsy the prostate and verify diagnosis.
85, 88, 89
 Factors that might influence PSA-
levels are important to assess as most prostate cancer in developed countries today are 
detected by a biopsy directly following a PSA-test.   
 
 
2.5.3 Weight change and prostate cancer 
While most previous studies have investigated the effect of BMI or another measure 
of body composition, few studies have had the opportunity to study weight change, 
which is in fact what causes a specific BMI, in relation to prostate cancer. Two 
previous studies have shown an association between high weight gain during 
adulthood and an increased risk of aggressive or fatal prostate cancer.
90, 91
 A large 
weight gain during adulthood has been associated with an increased risk of 
biochemical recurrence after a prostate cancer diagnosis and a weight gain around the 
time of a prostate cancer diagnosis has been associated with an almost doubled risk of 
cancer recurrence.
92, 93
 Further, a weight gain of ≥2.5kg in the year before a radical 
prostatectomy increased the risk of biochemical recurrence by 65% compared to men 
who gained less weight.
94
  
 
 
2.5.4 Physical activity and prostate cancer  
Another modifiable life-style factor with the potential to influence prostate cancer risk 
and progression is physical activity. Physical activity has been linked to reduced overall 
mortality in the general population and there is consistent evidence linking increased 
levels to reductions in all-cause mortality among cancer survivors.
95, 96
 Reductions in 
both breast cancer and colon cancer specific mortality has been shown whereas there is 
insufficient evidence for prostate cancer.
95
 Physical activity has been systematically 
investigated in relation to prostate cancer risk and was in a review and meta-analysis on 
the topic shown to be inversely associated with prostate cancer risk with a 10% risk 
reduction when comparing men in the highest and lowest groups of physical activity.
97
 
 
Few previous studies have been able to investigate the effects of post-diagnostic 
physical activity on prostate cancer progression and mortality. The first study, 
published by Kenfield et al.
98
, investigated the association between physical activity 
and mortality among men with prostate cancer. Their results showed that men who 
walked ≥90 min/week at a normal to very brisk pace had a reduced risk of all-cause 
mortality by 46% compared with walking for shorter durations at an easier pace. For 
prostate cancer specific mortality, walking briskly for longer duration was suggestively, 
but not statistically significantly, associated with a lower mortality rate. Men engaging 
in vigorous activity ≥3 h/week had a 49% lower risk of all-cause mortality and a 61% 
lower risk of prostate cancer specific death compared to men engaging in <1 h/week of 
vigorous activity. In a second study, Richman et al.
99
 investigated physical activity and 
prostate cancer progression and found that men walking briskly for ≥3 h/week had a 
57% lower progression rate compared to men walking for shorter durations at an easier 
pace. They also showed that, independent of duration, brisk walking was associated 
with a 48% decrease in progression rate compared to walking at an easy pace. A 
suggestive, but non-significant, inverse association between vigorous activity and 
prostate cancer progression was also seen.  
 
   15 
3 AIMS 
 
The overall aims of this thesis were to study associations between body weight and 
physical activity and prostate cancer risk, progression and mortality as well as to 
evaluate the validity of the web-based physical activity questionnaire “Active-Q”. 
 
Specifically, we aimed to: 
 
Study I 
Study associations between Body Mass Index (BMI) at the time of diagnosis of 
localized prostate cancer and progression, overall- and prostate cancer specific 
mortality as well as weight change after diagnosis and overall- and prostate cancer 
specific mortality 
 
Study II 
Study associations between physical activity after diagnosis of localized prostate cancer 
and overall- and prostate cancer specific mortality 
 
Study III 
Assess the validity and reproducibility of Active-Q against the doubly labeled water 
method with regards to total energy expenditure and against pedometers with regards to 
total physical activity  
 
Study IV 
Assess the validity and reproducibility of Active-Q against accelerometers with regards 
to time spent at different intensity levels 
 
Study V 
Study associations between BMI and serum PSA-levels as well as prostate cancer risk 
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4 METHODS  
  
4.1 VALIDATION STUDIES (STUDY III AND IV) 
 
4.1.1 Background 
In studies attempting to investigate an association between any exposure and an 
outcome, it is important to assess the validity of both the exposure assessment and the 
outcome to be able to take potential errors that may impact the results into 
consideration. Active-Q was originally developed for the LifeGene-study, a large 
prospective population based cohort.
20
 In addition to clinical data collected at specific 
health centers, large amounts of information regarding lifestyle factors were to be 
collected entirely via the Web. When LifeGene was initiated, physical activity 
questionnaires were in general paper-based and not developed or validated for web-
based use. Therefore, Active-Q was created and by efficient use web-based features, 
e.g. screening questions and follow-up patters, it was possible to create a questionnaire 
that only took a few minutes to respond to, yet assessed detailed information on 
physical activity. To validate Active-Q, the VALMA-study was performed during the 
spring of 2009 (Study III). The study population comprised adults, many young, and 
both men and women to reflect the future study participants in LifeGene. Thereafter, 
Active-Q was also included to measure physical activity in the large population-based 
STHLM-2 cohort which includes middle-aged and older men.
100
 Since this study 
population is differed from that in LifeGene, we performed a second validation of 
Active-Q within the STHLM-2 study population (Study IV). During the spring of 2012 
we began data collection for the VALTER-study. In Study III and IV, Active-Q is 
validated with regards to measuring total energy expenditure and time spent at different 
activity levels against the DLW method and accelerometers, respectively. 
 
 
4.1.2 The Active-Q Physical Activity Questionnaire 
Active-Q is a web-based, interactive physical activity questionnaire assessing habitual 
activity in adults >18 years of age. Physical activity during the past months is assessed 
within the four domains of; daily occupation, transportation, leisure time activities, and 
regular sporting activities. Additional sleeping hours are also assessed. A screening 
question assessing working status preceded the questions on daily occupation and 
subjects who respond that they are not working do not have to respond to questions 
related to occupation. Initial screening questions listing all the activities included in 
each domain are posed for transportation, leisure time activities and sporting activities. 
Only activities selected by the respondent in the screening are followed up regarding 
frequency and duration to reduce the total number of questions for each respondent. All 
questions have predefined answers of frequency and duration. Depending on the 
respondent’s answers to screening questions and the resulting follow-up patterns, the 
total number of questions responded to range between 9 and 47 in the present version 
of the questionnaire. Active-Q was modified slightly after the first validation study and 
questions on sleeping hours and working status were added and alterations to the 
included sporting activities were made. All activities in Active-Q are linked to MET-
values which enable classification into different levels of intensity and allows for 
calculations of energy expenditure.  
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4.1.3 Study design - VALMA 
Data from the VALMA (VALidation of Methods Assessing diet and physical activity) 
study is analyzed in Study III. VALMA was originally designed and conducted to 
evaluate the validity and reproducibility of both a new web-based food frequency 
questionnaire, Meal-Q, and the physical activity questionnaire Active-Q.
101-103
 The 
dietary part of the study design and the validity of Meal-Q, have been described 
previously and is beyond the scope of this thesis.
102, 103
 
 
Study participants included men and women, aged 20 to 65 years, recruited during the 
spring of 2009 through public advertisements in Stockholm, Sweden. Requirements for 
participation included having an email address and access to the Internet. Participants 
were not allowed to be on any weight alteration diet, pregnant, or having given birth 
during the ten months prior to study start. In total, 180 healthy adults were recruited, 
there among a sub-group of 40 individuals included in DLW analyses. All participants 
were provided oral and written information before giving their written informed 
consent prior to study start. The study was approved by the Research Ethics Committee 
at the Karolinska Institutet, Stockholm, Sweden. 
 
The design of the physical activity validation part of VALMA is shown if Figure 6. 
The total time of participation was 21 days. At an introductory meeting on day one, 
participants signed an informed consent, had their weight (kg) measured and received a 
pedometer for recording of steps. The first Active-Q questionnaire was emailed to 
participants on day seven and steps were self-recorded in a Web-based program during 
day 8 to 14. The second Active-Q questionnaire was emailed to participants on day 21, 
seven days after completing the registration. Individual usernames and passwords 
served as unique identifiers when responding to the questionnaires and recording steps. 
Directly following the first Active-Q responded to, participants were asked to respond 
to a short evaluation of the questionnaire and additional questions of current height, 
weight, level of education, and tobacco use. Study participants in the DLW sub-group 
were given the oral DLW dose on the first day of the study, collected their first urine 
sample on study site and thereafter collected one urine sample per day during the 
following ten days before returning the samples to study personnel. 
 
 
 
 
4.1.3.1 Study participants  
Out of the 180 initial participants in the VALMA-study, those not completing the study 
were excluded from analysis (n=3). Additionally, participants with incomplete data 
from the first Active-Q responded to, i.e. <1 hour of leisure time and sport activities 
together (n=6), who did not register their steps or who had registered <6 days of 
pedometer measurements (n=13) were excluded. In total, 158 participants were 
Figure 6. Study design of VALMA showing the timing of measurements using doubly labelled water 
(DLW) including collection of urine samples, pedometer registration, and response to the two 
Active-Q questionnaires (Active-Q-I and Active-Q-II) distributed. 
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included in validity analyses of Active-Q compared to pedometer data. The DLW sub-
group originally comprised 40 participants of which 36 remained after the previous 
exclusions and the exclusion of one additional subject with implausible DLW data. For 
reproducibility analysis, participants with incomplete data from the second 
questionnaire were also excluded (n=8) leaving 150 participants in analysis.  
 
4.1.3.2 Active-Q in the VALMA-study 
Energy expenditure from Active-Q was calculated based on the assumption of 1 MET 
being equal to 1kcal ∙ kg-1 ∙ hour-1.19 To calculate the energy expenditure from activities 
in Active-Q, the activity’s MET-value was multiplied by the respondents’ weight, 
reported daily duration of the activity, and by a factor of 4.184 to convert values from 
kcal to kJ: EEactivity(kJ/day) = METactivity ∙ Weight(kg) ∙ Durationactivity(h/d) ∙ 4.184. The 
crude total energy expenditure was estimated by summarizing the energy expenditure 
from all activities in Active-Q. Additional estimations of the total energy expenditure 
adjusted to 24-hours were calculated by adding eight hours of sleep to the crude 
estimate and compensating for all time diverging from 24-hours by adding or 
subtracting time using a MET-value of 2.0.
19, 104
 
 
4.1.3.3 The Doubly labelled water method (DLW) 
DLW was used to measure the average total daily energy expenditure during 11 
consecutive days. In brief, standard DLW doses were prepared following a similar 
strategy to that of Trabulsi et al.
105
 where a bulk dose of DLW was made by adding 44 
g of
 2
H2O (99.98% sterility tested, CK Gas Products Ltd, Hampshire, UK) to 1 L 10% 
normalized H2
18
O (SerCon Ltd, Cheshire, UK). Participants self-reported their body 
weight prior to study entry and those with a weight <75 kg or >75 kg were given 108 
and 141 g of the bulk dose, respectively. A pre-dose urine sample was collected at 
study site before drinking the DLW and additional daily urine samples (5 ml, excluding 
the morning void) were collected during the following 10 days. Participants recorded 
the date and time of collection on each sample tube and kept the samples refrigerated 
before returning them to the study team.  Samples were thereafter sent to the Medical 
Research Council, Human Nutrition Research, Cambridge, UK, for isotopic analysis,  
 
Previous studies have described the principles of analyses of the isotopic enrichment in 
the samples
106, 107
, and the slightly modified procedure used in the present study has 
also been described in more detail.
101
 Isotope ratio mass spectrometry was used for 
analyses of the ratio between 
2
H and 
1
H. Assessment of the
18
O/
16
O ratio was made 
using a continuous-flow isotope ratio mass spectrometer. Each batch of samples 
analyzed included analytical standards prepared in-house and traceable to the 
international standards, Vienna Standard Mean Ocean Water and Standard Light Arctic 
Precipitation. Using the equation by Schoeller et al.
108
, total CO2-production was 
estimated from the slopes and intercepts of isotope disappearance curves using data 
from urine samples collected on day 1-3 and 8-10. Total energy expenditure was 
calculated using the modified Weir equation
44
 and a respiratory quotient (RQ) of 0.85. 
 
4.1.3.4 Pedometers 
An activity registration using pedometers was performed during seven consecutive 
days. Participants received a pedometer and were instructed to wear it at their waistline 
during time awake but to remove it when performing water activities. Total number of 
daily steps was self-recorded by participants in a web-based program. The average 
number of daily steps calculated for all participants who had registered at least six days. 
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4.1.4 Study design – VALTER 
Data from the VALTER-study (VALidation against acceleromeTER) was analyzed in 
Study IV. VALTER was designed and conducted to evaluate and assess validity of 
Active-Q within a male population in which the questionnaire was already in use. All 
study participants responded to Active-Q on the Web twice and wore a GENEA-
accelerometer
109
 during seven consecutive days on two occasions. In addition, a 
calibration study of the accelerometers was also performed within a sub-group of 
participants to determine cut-points for classifying accelerometer data as 
sedentary/light, moderate or vigorous. 
 
Study participants were recruited from the STHLM-2 cohort comprising men who 
during 2010 to 2012 underwent PSA-testing in Stockholm County, Sweden. 
Participants that enrolled in the cohort between March and May 2012 and who had 
agreed to be contacted for additional studies were invited to participate in VALTER. 
An invitation was emailed to 1,348 men in September 2012. Those who replied to the 
invitation were sent more detailed study information and were scheduled for an 
introductory meeting at Karolinska Institutet. All participants were given both written 
and oral information about the study and signed an informed consent prior to 
participation. In total, 167 men agreed to participate. The Research Ethics Committee at 
Karolinska Institutet, Stockholm, Sweden, approved the study. 
 
Each participant was enrolled in VALTER during four weeks, the study design is 
shown in Figure 7. Participants attended an introductory meeting on day one of the 
study and received the first accelerometer to wear for seven days. Participants were 
instructed to wear the accelerometer continuously on their left wrist, irrespective of 
handedness, but to remove it during water-based activities. As a complement, they were 
also given a diary in which all occasions when the accelerometer was removed were to 
be noted. The first Active-Q questionnaire was administered via email later the same 
day and also included background questions on height, weight, year of birth, education 
level and handedness. After seven days, the accelerometer and the diary was returned to 
the research group via regular mail using a padded envelope with prepaid postage. 
Three weeks later, participants attended a second meeting and there received the second 
accelerometer to wear during seven days. The second Active-Q was administered via 
email later the same day and participants returned the accelerometer and the diary to the 
research group after seven days. Individual user-names and passwords served as 
identifiers for the questionnaires and the accelerometers had unique serial-numbers.  
 
 
 
 
A calibration of the accelerometers was performed in a sub-group of 22 participants 
who each wore two accelerometers on the same wrist while performing five predefined 
activities including: sitting, standing, walking at a pace of 3.2, 4.8 and 6.4 km/h (2, 3 
and 4 mph). Each activity was performed for five minutes under supervision of study 
Figure 7. Study design of VALTER showing the timing of measurements using the GENEA 
accelerometer on two occasions and responding to the two Active-Q questionnaires (Active-Q-I 
and Active-Q-II) distributed. 
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personnel and counts from the middle three minutes of each activity performed were 
extracted for analysis. 
 
4.1.4.1 Study participants 
In total 167 men who agreed to participate in the VALTER-study. Out of them, men 
who did not complete the study (n=2) and men who had erroneous accelerometer data 
from the first (n=3) or second (n=4) week of accelerometer measurements were 
excluded. Additionally, as the accelerometer was worn on the left wrist, only men who 
reported being right-handed in the first questionnaire were included in analysis leaving 
11 left handed-men for exclusion. In total, data from 148 men was analyzed.  
 
4.1.4.2 Active-Q in the VALTER-study 
Reported time spent at different activity levels was calculated by classifying activities 
in Active-Q into light-, moderate- or vigorous physical activities depending on the 
MET-value for each activity. Activities with a MET-value <3, 3-6 or >6 were classified 
as light, moderate or vigorous activity, respectively. An additional category of 
moderate-to-vigorous physical activity was also created and included all activities with 
a MET-value of 3 or above. Total time reported in each category was summarized.  
 
4.1.4.3 The GENEA accelerometer 
The GENEA (Gravity Estimator of Normal Everyday Activity) monitor (Figure 8) is a 
small and tri-axial accelerometer measuring vertical, anteroposterior and mediolateral 
movement at a rate up to 80 Hz with a dynamic range of ±6 g.
109
 In the VALTER-
study, acceleration was sampled at 40 Hz. The GENEA post-processing software 
(version 1.2.1) was used to summarize the raw 40 Hz tri-axial data into a signal 
vector magnitude (SVM) (gravity subtracted), by 𝑆𝑉𝑀𝑔𝑠 = ∑ |√𝑥2 + 𝑦2 + 𝑧2 − 𝑔|. 
In the original GENEA software, g was assumed to be 1.00. The post-processing 
software output represents a mean r-g value per second during each specific minute. 
To obtain results as 1 minute epochs the output was multiplied by 60, resulting in the 
same effect as summarizing 60 1-s epochs. Since measures had been made at 40 Hz, 
the output was multiplied by 2 to make results comparable to a previous study using 
GENEA sampling at 80 Hz.
109
 The SI unit of the outcome variable is g-seconds (g·s).  
 
 
 
In the additional calibration study, cut-points for classification of the GENEA output 
into different levels of intensity were developed for our specific study population. The 
SVMgs for each measuring point of each activity performed during the calibration was 
calculated and plotted against the activities corresponding MET-value. The resulting 
straight line equation 𝑦 = 0.0019𝑥 + 1.3165  was used to generate cut-points for 
accelerometer out-put corresponding to MET-values of 3.0 and 6.0, see Figure 9. 
 
Figure 8. The GENEA-monitor is a small tri-axial 
accelerometer measuring vertical, anteroposterior 
and mediolateral movement. 
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For analysis in the present study, data from six complete days was extracted from each 
week of accelerometer measurements starting at midnight on the first day the 
accelerometer was worn. Each minute output from the GENEA accelerometer with a 
SVMgs of <961, 961≤2628 and >2628 were classified as light, moderate and vigorous 
activity, respectively. A combined category of moderate-to-vigorous activity was also 
created. Non-wear time recordings of activities with a MET-value >3 were corrected 
for by subtracting time from the light category and adding time to the moderate or 
vigorous categories depending on reported activity. 
 
 
4.1.5 Statistical analysis 
All analyses were performed using STATA version 13.0 (STATA Corporation, College 
Station, TX, USA). The significance level was set to α = 0.05. The significance level is 
represented by p-values which tell us the strength of evidence against the null-
hypothesis (i.e. that the true difference in the population is zero) given the data in our 
sample. The threshold of 0.05 is arbitrary but commonly used. 
 
4.1.5.1 Descriptive analysis 
Characteristics of participants in VALMA (Study I) and VALTER (Study II) are 
presented as absolute numbers and percentages and mean values and standard 
deviations (SD). In addition, the total range of quantitative variables and the 
interquartile range (IQR) are presented. Potential differences between groups were 
tested for using t-tests and chi-square tests for continuous and categorical variables 
respectively. A t-test compares the mean values of a variable between two groups while 
a chi-square test compares the distribution of a variable between the groups. 
 
4.1.5.2 Validity analysis 
The degree of association between the results from Active-Q and the reference method 
was assessed using Spearman rank correlation coefficients with confidence intervals 
Figure 9. Displaying MET-values of the five activities performed during the calibration (x-axis) 
and average GENEA-output in SVMgs (y-axis) for each specific activity (n=22, 44 measuring 
points). Cut-offs for SVMgs at MET-values 3 and 6 estimated using the resulting linear equation 
 𝑦 = 0.0019𝑥 + 1.3165 are marked in the figure.  
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(CIs) obtained using the bootstrap method.
110
 Total energy expenditure assessed with 
Active-Q and DLW was compared in the VALMA-study while the degree of 
association between times spent at light, moderate, vigorous or moderate-to-vigorous 
activity levels assessed between Active-Q and the GENEA accelerometer was assessed 
in the VALTER-study. A correlation coefficient (r), tells us the strength of a linear 
association between two variables. It ranges between -1 and 1 equals 0 if there is no 
correlation and -1 or 1 if there is a perfect straight negative or positive correlation. 
Spearman’s rank correlation is non-parametric and based on ranks. The bootstrap 
method is a way of deriving confidence intervals (CIs) using resampling with 
replacement. 
 
4.1.5.3 The Bland-Altman method 
In addition to the Spearman correlation coefficients which do not detect systematic 
differences between methods, the Bland-Altman technique
111
 was applied. The Bland-
Altman plot provides a graphical evaluation of the association and is used to assess 
systematic differences and absolute agreement. It enables visual assessment and depicts 
the magnitude of measurement error and potential bias that might vary across the 
assessment range. The difference between the two methods is plotted on the y-axis and 
the mean value of the methods is plotted on the x-axis. The limits of agreement, ±2SD 
of the difference, are marked in the plot and provide a measure of variation.  
 
4.1.5.4 Reproducibility analysis 
The reproducibility (i.e. the amount of measurement error) of duplicated measurements 
between two admissions of Active-Q in study I and II, and the two weeks of wearing 
the GENEA accelerometer in study II, was assessed by computing intraclass 
correlation coefficients (ICCs)
112
 using the ANOVA estimator. An ICC can range 
between 0 and 1 and represents the ratio of the between subject variance to the 
combination of the between and within subject (i.e. the measurement error) variance. 
The higher the ICC, the larger percentage of the total variability seen is due to between-
subject variability and not measurement error, i.e. an ICC equal to 1 means complete 
reproducibility and no measurement error.  
 
 
4.2 PROSTATE CANCER STUDIES (STUDY I, II AND V) 
4.2.1 Background 
Studies investigating potential associations between modifiable life-style factors, e.g. 
BMI and physical activity, and prostate cancer risk, progression and mortality are of 
great interest and public health concern. In Study I and II we investigate progression 
and mortality after a prostate cancer diagnosis and the impact of lifestyle. Modifiable 
lifestyle factors provide a unique opportunity for the individual himself to make 
choices, and potentially changes, to improve his own survival. In Study V we aim to 
assess the impact of BMI on the most common biological marker for prostate cancer 
diagnostics, PSA, as well as on prostate cancer risk. How important is it to consider a 
patient’s BMI when interpreting results of serum PSA-level and can men by changing 
their lifestyle and BMI impact their own prostate cancer risk? Data used in Study V is 
obtained from the STHLM-2 cohort which was one of the first large studies to use the 
Active-Q physical activity questionnaire (validated in Study III and IV). Although not 
the main exposure in Study V, Active-Q was used to assess total physical activity 
which may be a confounder for the association between BMI and baseline PSA-levels 
and the risk of being diagnosed with prostate cancer during follow-up.  
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4.2.2 Study design - PROCAP 
Data from the PROCAP (PROgression in CAncer of the Prostate)-study was analyzed 
in Study I and II.  PROCAP is a population-based cohort and the study was initiated in 
2007. Men diagnosed with localized prostate cancer between 1997 and 2002 were 
identified through the National Prostate Cancer Registry in Sweden
113
 and invited to 
donate a blood sample and responded to a questionnaire. The aim of the study was to 
identify how lifestyle and genetic factors influence prognosis and survival among men 
diagnosed with localized prostate cancer.  
 
PROCAP is an adjunct study to the National Prostate Cancer Registry (NPCR) of 
Sweden follow-up study, a retrospective, nationwide cohort study of patients with 
localized prostate cancer that has been described in more detail previously.
114
 In 
Sweden, all incident cancers are reported to the National Cancer Registry (NCR)
115
 
while the National Prostate Cancer Registry (NPCR) includes more detailed 
information on all patients with a prostate cancer diagnosis including; serum PSA-
levels, TNM-stage, tumor differentiation at time of diagnosis, and primary treatment 
within six months of diagnosis.
113, 116
 In short, patients registered with a localized 
prostate cancer in the NPCR between January 1st 1997 (January 1st 1998 in one 
region) and December 31st 2002; <=70 years of age at diagnosis, a diagnostic serum 
PSA <20 ng/ml, local tumor stage T1-T2, no signs of lymph node or bone metastasis 
(NX or N0 and MX or M0, respectively) were eligible for inclusion in the NPCR of 
Sweden follow-up study. In total, 8,304 patients fulfilled the criteria and 7,960 (96%) 
accepted inclusion to the study. Information on date of last follow-up, reason for and 
date of termination of surveillance, subsequent PSA testing, signs of local progress, 
and distant metastasis was retrieved on one occasion (median time: four years after 
diagnosis) for each patient and was extracted from medical records by research nurses 
in each of six health care regions in Sweden.    
 
All patients in the NPCR of Sweden follow-up study who were still alive in 2007 
(n=7,074) were invited to PROCAP. In total 5,779 patients (82%) accepted inclusion 
and were asked to donate a blood sample and respond to a questionnaire. Half of the 
study participants chose to respond to a paper-questionnaire which was scanned into 
digital format and half chose to respond to a Web-questionnaire where results were 
directly saved in digital format. Results were checked for completeness by study 
personnel. All patients gave their written informed consent for participation. The 
PROCAP study has been approved by the research ethics committee at Karolinska 
Institutet, Stockholm, Sweden. The study design is shown in Figure 10. 
 
 
 
The present thesis includes two studies based on PROCAP data. In Study I, the 
association between body weight (BMI at time of diagnosis and weight change after 
diagnosis) and prostate cancer progression, prostate cancer specific and overall 
mortality was investigated. In Study II, physical activity after diagnosis and prostate 
cancer specific and overall mortality was studied.  
Figure 10. Study design for PROCAP and years of data collection and date of follow-up. 
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4.2.2.1 Study participants  
Among the 5,779 men who accepted inclusion to PROCAP, those with missing clinical 
(n=290) and questionnaire data (n=341) were excluded from all analysis. In mortality 
analysis with BMI or weight change as exposures, men with missing data on BMI 
(n=60) were excluded. Additional exclusions of men without data on progression 
(n=712) were made for analysis of progression. In analysis of physical activity as the 
exposure, men with incomplete physical activity data (n=525) were excluded. Table 2 
show the final numbers of men included in analysis presented in this thesis. Results 
using updated information did not differ substantially from the published results. 
 
 
Table 2. Number of men included in analysis after study specific exclusions  
 
Analysis n Comment 
BMI and prostate cancer progression 4,376 Same as in publication 
BMI and mortality 5,088 Updated information since publication 
Weight change and mortality 5,088 Updated information since publication 
Physical Activity and mortality 4,623 Same as in publication 
 
 
4.2.3 Study design –STHLM-2 
Data from the STHLM-2 cohort was analyzed in Study V. All men referred to a PSA-
test in laboratories in Stockholm County between 2010 and 2012 were invited to 
participate in STHLM-2. Men who agreed to participate had their serum PSA-levels 
measured at the blood sampling visit for the PSA-test. Participants also donated 
additional blood and urine samples and were asked to respond to a questionnaire. A 
total of 24,966 men were included in the cohort that has been described previously.
100
 
Information on incident prostate cancers was obtained from the Swedish Cancer 
Registry (SCR)
115
 and additional information on prostate cancer was obtained through 
the National Prostate Cancer Registry (NPCR)
113
. Participants were followed-up 
through registry linkage until the end of April 2014. The local ethics committee at 
Karolinska Institutet, Stockholm, Sweden, approved the study.  
 
4.2.3.1 Study participants 
In the present study, participants were excluded for analysis for several reasons and in 
consecutive order as follow:  missing date of inclusion (n=34) or missing information 
on date of birth (n=101), missing questionnaire data (n=4,490), if having a prostate 
cancer diagnosis prior to inclusion (n=4,251), missing information on BMI (n=108) or 
PSA (n=52), and if reported BMI was <18.5 (n=61) or >50 kg/m
2
 (n=42). In total, 
15,829 men were included in the analysis of BMI and serum PSA-levels. A lag-time of 
six months was introduced for analysis of prostate cancer risk and men diagnosed with 
prostate cancer within 6 months of inclusion (n=500) were excluded to minimize 
reverse causation. The analysis of prostate cancer risk included a total of 15,329 men. 
 
 
4.2.4 National Registers  
4.2.4.1 The Swedish Cancer Register (SCR) 
The SCR was founded in 1958 and covers the whole population in Sweden.
115
 Data on 
prostate cancer diagnosis from the SCR was obtained for Study V. The registry holds 
three types of data including patient data (personal identification number, age, sex and 
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place of residence), medical data (for example tumor site, histological type and date of 
diagnosis), and follow-up data on date and cause of death and date of migration Health 
care providers are by law obligated to report newly detected cancers to the registry. 
Completeness of the SCR is high.
115 
 
4.2.4.2 The National Prostate Cancer Register (NPCR) 
The NPCR of Sweden exists in part to improve and promote health among men in 
Sweden and to increase knowledge of prostate cancer by improving treatment and 
survival. Study I and II are based on data from the NPCR of Sweden follow-up 
study.
114
 The NPCR includes detailed information on patients with a prostate cancer 
diagnosis and holds information on tumor stage, Gleason score, serum PSA-level and 
primary treatment.
113
 The first regional prostate cancer register was started in 1987 in 
the south-east health care region in Sweden. Additional regions in the country followed 
the initiative during the 1990’s. From January 1st 1998, the NPCR of Sweden includes 
all health care regions in the country. The registry has shown that information in the 
NPCR is of high quality and the registry captures >98% of all prostate cancer cases 
recorded in the Cancer Registry.
116
  
 
4.2.4.3 The Cause of Death Register (CDR) 
The CDR hold information on the deaths of all Swedish citizens, irrespective of the 
whether they died in Sweden or outside the country, and is complete from January 1
st
 
1969.
117
 Diagnoses are coded according to the international versions of ICD. 
Information on date and cause (prostate specific or other) of death was obtained from 
the CDR in Study I and II.  
 
 
4.2.5 Assessment of exposures, outcomes and covariates 
4.2.5.1 Exposure definitions 
In Study I and II, current height, weight, and weight change since diagnosis was self-
reported in the PROCAP questionnaire. Body mass index (BMI, kg/m
2
) at diagnosis 
was estimated based on self-reported current height and weight, and weight change. 
In Study V, BMI at baseline was calculated based on self-reported current weight and 
height in the STHLM.2 questionnaire. Men were categorized by BMI as normal weight 
(<25 kg/m
2
), overweight (25<30 kg/m
2
) or obese (BMI ≥30 kg/m2) in Study I and II. 
In study V, an additional category of BMI was included and men were categorized as 
normal weight (<25 kg/m
2
), overweight (25<30 kg/m
2
), obese level 1 (BMI 30<35 
kg/m
2
) and obese level II (BMI ≥35 kg/m2). BMI classifications were made as defined 
by the National Institute of Health.
10
 
 
Study participants in PROCAP who reported a weight change were asked how many 
kilograms that was gained or lost. Based on the reported current weight and weight 
change, the percent weight change since diagnosis was calculated.  Patients were 
thereafter categorized into three groups of: no change or a change <5 %, an increase 
in weight ≥5 % or a decrease in weight ≥5 %. 
 
Physical activity in PROCAP was assessed using previously validated questions.
104
 
Participants were asked to report the daily time spent walking/bicycling and 
performing household work and the weekly time spent exercising "after diagnosis." 
Each activity category was assigned a MET-value using the Compendium of Physical 
Activity: walking/bicycling (MET=3.6), household work (MET=2.5) and exercise 
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(MET=5.5).
20
 Daily time spent walking/bicycling had seven response intervals 
specified, household work six and exercise seven. In further analysis, the response 
intervals for each variable was combined and divided into two levels of exposure: 
walking/bicycling as <20 and ≥20 min/day, household work as <1 and ≥1 h/day, and 
exercising as <1 and ≥1 h/week. The reported time spent walking/bicycling, 
performing household work, and exercising was also multiplied by the activity 
specific MET-values and a categorical variable of recreational MET-hours per day 
with 2 levels (<5 and ≥5 MET-h/d) was created.  
 
4.2.5.2 Outcome definitions 
Disease progression is analyzed in relation to BMI in Study I and was defined 
according to primary treatment. Among those treated with curative intent (radiation 
therapy or radical prostatectomy), experiencing biochemical recurrence, local 
progress, or distant metastasis, was considered disease progress. Further, biochemical 
recurrence was defined differently depending on primary treatment.
118
 For patients 
who underwent radiation therapy, biochemical recurrence was defined as a doubling 
in PSA above the post-treatment nadir value and exceeding at least 1 ng/ml. Among 
those treated with radical prostatectomy, two consecutive tests with PSA-levels >0.2 
ng/ml defined biochemical recurrence (the date for this event was set to the first 
occasion). Among operated patients with only one registered PSA-test, a value>0.5 
ng/ml was considered biochemical recurrence. Lastly, the event of termination of 
deferred treatment with biochemical progression as the reason for termination defined 
progress in patients on surveillance. Time to event in analysis was defined as the time 
from date of prostate cancer diagnosis to the date of the earliest observed progressive 
event for each treatment-specific definition. Patients on surveillance who ended their 
deferred treatment without any signs of disease progression were censored at the 
recorded date of termination and patients with no progressive event were censored at 
the last recorded date of follow-up.  
 
Prostate cancer specific mortality and overall mortality are analyzed in relation to 
BMI and weight change in Study I and physical activity in Study II. Information on 
the he date of death and cause of death (prostate cancer specific or other) were 
obtained from the Swedish Cause of Death Registry using national identification 
numbers. Time to event in analysis was defined as time from date of prostate cancer 
diagnosis to the date of death reported in the registry or censoring at the end of 
follow-up on December 31
st
, 2012, whichever came first. Time since prostate cancer 
diagnosis was used as the underlying time scale in analysis and all patients were left 
truncated by study design at the date of inclusion to PROCAP. 
 
In Study V, serum PSA was measured at baseline. Due to a skewed distribution, the 
variable was logarithmically transformed (log-PSA) before analysis to create a normal 
distribution. Further, information on incident prostate cancers was obtained from the 
NCR. Outcome end points were the first event of date of diagnosis, death or last 
registry linkage (April 22
nd
) 2014. To define prostate cancers according to severity, 
additional prostate cancer specific information was obtained through the NPCR and 
prostate cancers with a Gleason score <7 or ≥7 were defined as low- and high-grade.  
 
4.2.5.3 Assessment of potential confounding factors 
Additional lifestyle factors considered as potential confounders in Study I and II 
were: tobacco use, total energy intake, education level, overall stress during the last 
year, current occupation, and family history of prostate cancer were assessed. 
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Physical activity at age 50 was included as a potential confounder in analysis of BMI 
and weight change (Study I) and BMI and weight change were considered 
confounding factors in analysis of physical activity (Study II). Clinical variables 
including: PSA-level at diagnosis, TNM-stage, tumor grade and Gleason score at 
diagnosis, and primary treatment were also considered as potential confounders. Cut-
points for categorical variables were based on established strata or arbitrarily defined 
prior to analysis. In Study V, factors considered as potential confounders were assessed 
at baseline and included: age at inclusion, education level, smoking status, level of 
stress, family history of prostate cancer and physical activity derived from Active-Q.  
 
 
4.2.6 Sensitivity analysis 
In analysis of mortality (Study I and II) sensitivity analysis where men who died 
within 18 months of responding to the questionnaire were carried out. In Study V, 
sensitivity analysis with a lag-time of 6 months was carried out. The lag-time was 
introduced to examine if the exposures potentially had been affected by illness which 
may also be associated with death (Study I and II) or prostate cancer (Study V), i.e. 
reversed causality. 
 
 
4.2.7 Statistical analysis 
All analyses were performed using STATA version 13.0 (STATA Corporation, College 
Station, TX, USA). The significance level was set to α = 0.05. 
 
4.2.7.1 Characteristics  
Distributions and means of demographic and clinical variables were studied across 
BMI categories (Study I and V) and groups of total recreational MET-h after diagnosis 
(Study II). Statistically significant associations were tested for using chi-square test for 
categorical variables and one-way ANOVA for continuous variables. Differences in 
HRs for men in the different exposure categories were compared using the log-rank 
test. Progression free (Study I), overall and prostate cancer specific survival (Study I 
and II) were analyzed using the Kaplan-Meier method to estimate survival curves 
graphically displaying the cumulative survival probability on the y-axis against follow-
up time on the x-axis. For results from log-rank tests and Kaplan-Meier curves we refer 
to paper I and II. 
 
4.2.7.2 Multivariable linear regression 
In Study V, the association between BMI and serum PSA-levels at baseline was 
assessed using multivariable linear regression models. A regression analysis gives an 
estimation of the relationship between a continuous numerical dependent outcome 
variable and one or more independent exposure variables, which may or may not be 
continuous. A linear regression model estimates the best fitting linear function, i.e. the 
best fitting straight line between outcome and exposure variables, to describe an 
association. Because of the logarithmic transformation of the outcome variable, results 
are interpreted as percent change in serum PSA-levels with increasing BMI. BMI was 
included in models both as a continuous and categorical exposure. The association 
between BMI and serum PSA was studied separately for all men, men diagnosed with 
prostate cancer during the follow-up, and men without a diagnosis during follow-up. 
Unadjusted, age-adjusted and multivariable-adjusted regression models were fitted.  
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4.2.7.3 Cox proportional hazards regression 
To study the effect of an exposure on the time-to-event (progression or death), survival 
analysis assessing the exposures effect on the outcome per time-unit, creating event 
rates, were used. The Cox proportional hazards regression compares the hazards 
among exposed and unexposed. It relies on the assumptions that the ratio of the hazards 
between the two groups is constant over the time scale and that it is based on 
considering risk sets of the individuals who are still at risk each time an event occurs. 
The proportional hazards assumption was tested using Schoenfelds residuals. No 
statistically significant deviations from the assumption were seen in Study I, II or V. 
The reliability of the point estimate (i.e. the HR) is given by the 95% confidence 
interval which provides a range of values which we are fairly confident to include the 
“true” population estimate. If we were to repeat the same study many times, assuming 
that all variation is random, we would find the “true” estimate in 95% of the samples. 
 
Cox proportional hazards regression models were fitted to estimate unadjusted, age-
adjusted and multivariable-adjusted hazard rate ratios (HRs) with 95% confidence 
intervals (95% CIs) in the analysis of risk, progression and mortality. In Study I and II, 
the underlying time scale was time since prostate cancer diagnosis and patients were 
left truncated by study design at the date of inclusion to PROCAP. All exposure 
variables were included as categorical exposures in the models. End points in analysis 
of progression were the earliest observed progressive event as defined in paragraph 
4.2.5.2 or last date of follow-up. In mortality analysis, end points were date of death or 
last date of follow-up (Dec 31
st
 2012), whichever came first. In Study V, BMI was 
analyzed both as continuous and categorical. Time from inclusion to STHLM-2 was 
used as the underlying time-scale. End points were date of diagnosis, death or last 
registry linkage (April 22
nd
) 2014, whichever came first.  
 
4.2.7.4 Selection of confounding factors 
To assess potential confounding by measured covariates, we tested if the covariates 
were statistically associated with both the exposures and the outcomes. The association 
between covariates and exposure was assessed using linear regression models and the 
association between covariates and outcome was assessed using Cox proportional 
hazards models. Covariates were considered confounders and included in multivariable 
adjusted models if statistically significantly associated with both the exposures and the 
outcomes or if prior subject matter knowledge indicated an association. 
  
4.2.7.5 Survival splines 
Survival splines were used in Study V. To illustrate the dose-response relationship 
between serum PSA-levels and BMI, natural (cubic) linear regression splines were 
fitted with knots at BMI=25 and 30 kg/m
2 
.
119
 To summarize the fitted spline models, 
regression standardization was used, in which the predicted means obtained from the 
multivariable adjusted spline function are standardized to the confounder distribution in 
the sample.
5
 Separate analyses were made for all men, men diagnosed with prostate 
cancer during the follow-up, and men not diagnosed during follow-up. To illustrate the 
association between BMI and prostate cancer risk, natural (cubic) Cox regression 
splines were fitted with knots at BMI=25 and 30 kg/m
2
, and summarized through 
regression standardization. This analysis produces standardized “survival” (i.e. cancer-
free) probabilities, as a function of time since inclusion into the study. The association 
between BMI and prostate cancer risk was studied separately for all cancer types, low-
grade, and high-grade cancer, respectively.  
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5 RESULTS 
 
5.1 VALIDATION STUDIES  
 
5.1.1 Characteristics - VALMA 
Characteristics of study participants are displayed in Table 3. A majority of the study 
participants were women (n=124, 78%), had >12 years of education (n=129, 82%), and 
were mostly never smokers (n=107, 69%). No differences were seen between men and 
women with regards to education or smoking status but more women than men had a 
BMI <20 kg/m
2
 while current snuff use was more common among men. There were no 
differences between the sexes with regards to crude energy expenditure (not adjusted) 
assessed with Active-Q, total MET-hours/day or average number of daily steps. 
However, men had a higher total energy expenditure (adjusted to 24-hours) assessed 
with Active-Q and DLW compared to women. No differences of characteristics were 
seen between participants in the DLW sub-group and the other participants.  
 
Table 3. Characteristics and results from measurements in the VALMA study (n=158) 
 
 Mean (SD) Median Min-Max IQR 
Age, years 32.6 (11.6) 28 21-63 24-38 
BMI, kg/m
2
 23.1 (3.8) 22.7 16.3-44.7 20.7-24.1 
Active-Q-I      
 Energy expenditure
1
, kj/day 6,599 (3,278) 5,959 1,618-22,872 4447-7738 
 Total energy expenditure
2
, kj/day 11,630 (2,867) 11,264 5,507-22,644 9,579-12,963 
 Total MET-hours/day 22.4 (10.2) 20.9 4.3-88.2 16.0-26.1 
Active-Q-II
3
      
 Energy expenditure
1
, kj/day 6,270 (2,747) 5,602 1,576-15,798 4,423-7,209 
 Total energy expenditure
2
, kj/day 11,718 (2,772) 11,380 5,983-20,853 9,917-12,750 
 Total MET-hours/day 21.3 (7.9) 20.1 3.7-52.3 16.0-24.9 
Reference measures      
 Total energy expenditure DLW
4
, 
kj/day 
11,207 (2,284) 10,924 7,375-17,310 9,858-12,057 
 No. daily steps 8,533 (3,042) 8,194 2,513-18,410 6,579-10,047 
1
Crude, 
2
Adjusted to 24-hours, 
3
n=150, 
4
DLW sub-group, n=36.  BMI, Body Mass Index; DLW, Doubly 
Labelled Water; kJ, kilo-joule; IQR, Interquartile range 
 
 
 
5.1.2 Characteristics - VALTER 
Characteristics of participants in the VALTER-study are shown in Table 4. Half of the 
participants had an education >12 years (n=74, 50%), 57% reported to be working full- 
or part-time (n=85) and a slightly more than half were ≥65 years of age (n=81, 55%). 
Men <65 years of age reported working to a higher degree than men >65 years. In 
accelerometer measurements, men <65 years of age had fewer minutes spent in light 
physical activity and more minutes spent in moderate and moderate-to-vigorous 
physical activity. There was a borderline statistically significant difference in time 
measured spent in vigorous physical activity. There were no differences between the 
age groups with regards to reported time on any activity level in Active-Q. 
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Table 4. Characteristics and results of time spent in light, moderate, vigorous and moderate-to-
vigorous (LPA, MPA, VPA and MVPA, respectively) physical activity levels in the VALTER study (n=148) 
 
 Mean (SD) Median Min-Max IQR 
Age, years 65.4 (8.7) 66 33 – 86  61 – 71  
BMI, kg/m
2
 25.7 (2.9) 25.4 19.6 – 35.6   23.5 – 27.5  
Active-Q-I      
 LPA min/day 1,301 (123) 1,339 849 – 1,440 1,281 – 1,382  
 MPA min/day 121 (120) 84 0 – 555 51 – 135  
 VPA min/day 18 (26) 6 0 – 130 0 – 29  
 MVPA min/day 139 (123) 101 0 – 591 58 – 159  
Active-Q-II      
 LPA min/day 1,301 (139) 1,355 680 – 1,428 1,275 – 1,390  
 MPA min/day 116 (123) 69 0 – 557 41 – 148  
 VPA min/day 22 (42) 9 0 – 289 0 – 29  
 MVPA min/day 139 (139) 85 12 – 760 50 – 165  
GENEA reference measures      
 LPA min/day 1,392 (28) 1,393 1,255 – 1,437 1,380 – 1,409  
 MPA min/day 46 (27) 44 3 – 182 31 – 56  
 VPA min/day 3 (6) 1 0 – 43 0 – 3  
 MVPA min/day 48 (28) 47 3 – 186 32 – 60  
IQR, Interquartile range 
 
 
5.1.3 Validity 
5.1.3.1 Compared to doubly labelled water (DLW) 
Spearman correlation coefficients between energy expenditure without and with 
adjustments to 24-hours and total MET-hours assessed with Active-Q and total energy 
expenditure measured with DLW were r=0.43 (95% CI: 0.19-0.67), r=0.52 (95% CI: 
0.32-0.71) and r=0.28 (95% CI: -0.05-0.60), respectively. Bland-Altman plots showing 
the absolute agreement between the two methods are shown in Figure 11. Without 
adjustments to the energy expenditure from Active-Q, the mean difference between the 
methods was -4147kJ. When results were adjusted to total energy expenditure during 
24-hours, the mean difference between the methods was 447 kJ. The plots showed no 
clear trends of proportional error or differences between men and women. 
 
 
Figure 11. Bland-Altman plots of the absolute agreement between energy expenditure assessed with 
Active-Q and doubly labelled water (DLW). Each point represents one participant (n=36). The mean of 
the two methods is displayed on the x-axis while the absolute difference is displayed on the y-axis.  
a. Energy expenditure assessed with Active-Q (without adjustments) , b. Total energy expenditure 
assessed with Active-Q (adjusted to 24-hours) and DLW 
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5.1.3.2 Compared to pedometers 
Spearman correlation coefficients between energy expenditure with and without 
adjustments to 24-hours and total MET-hours assessed with Active-Q and the average 
number of daily steps measured were r = 0.07 (95%CI: -0.11-0.25), r = -0.12 (95%CI: -
0.23-0.02) and r = 0.20 (95%CI: 0.08-0.33), respectively. Similar results were obtained 
in analysis of men and women separately (data not shown). 
 
5.1.3.3 Compared to the GENEA accelerometer 
Spearman correlation coefficients between time spent in light, moderate, vigorous and 
moderate-to-vigorous physical activity assessed with Active-Q (adjusted to 24-hours) 
and average time per day from GENEA measurements were r = 0.35 (95%CI: 0.19-
0.51), r = 0.27 (95%CI: 0.11-0.43), r = 0.54 (95%CI: 0.41-0.67) and r =0.35 (95%CI: 
0.20-0.50), respectively. Correlation coefficients among men <65 years were slightly 
lower for all categories except vigorous activity (data not shown). For men ≥65 years, 
correlation coefficients were higher for all categories except vigorous activity (data not 
shown). Bland-Altman plots showing the absolute agreement between times at different 
intensity levels assessed with Active-Q and accelerometers are shown in Figure 12. 
The mean difference between the methods (Active-Q minus GENEA) was -91, 76, 15 
and 91 min/day for light, moderate, vigorous and moderate-to-vigorous physical 
activity, respectively. Clear trends of decreased accuracy with increasing time spent in 
moderate and vigorous activities was seen while a decreased accuracy at less time spent 
in light physical activity was seen. Men <65 years appear to over-report vigorous 
activities to a greater extent than older men.  
 
Figure 12. Bland-Altman plots of the absolute agreement between times spent at different activity 
levels assessed with Active-Q and GENEA accelerometers. Each point represents one participant 
(n=148). The mean of the two methods is displayed on the x-axis while the difference is displayed on 
the y-axis. a) Light Physical Activity (LPA) b) Moderate Physical Activity (MPA) c) Vigorous Physical 
Activity (VPA) d) Moderate-to-Vigorous Physical Activity (MVPA) 
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5.1.4 Reproducibility 
Intraclass correlation coefficients (ICCs) for variables of energy expenditure with and 
without adjustments to 24-hours and total MET-hours assessed in the first and second 
Active-Q were r = 0.74 (95%CI: 0.67-0.81), r = 0.87 (95%CI: 0.83-0.91) and r = 0.66 
(95%CI: 0.56-0.75), respectively. Results were similar for men and women separately 
although ICCs for women were slightly higher than those for men (data not shown) 
 
ICCs for variables of time spent in light, moderate, vigorous and moderate-to-vigorous 
physical activity assessed in the first and second Active-Q responded to were r = 0.67 
(95%CI: 0.58-0.76), r = 0.69 (95%CI: 0.60-0.77) , r = 0.51 (95%CI: 0.39-0.63) and r = 
0.67 (95%CI: 0.58-0.76), respectively. While results were similar for men <65 and ≥65 
years of age for time spent in vigorous activities, ICCs were slightly higher among the 
older men compared to the younger for the other three categories (data not shown). 
 
 
5.1.5 Active-Q in VALMA and VALTER 
Results from Active-Q were similar on a group level when comparing variables of 
energy expenditure, total MET-hours and time spent at different intensity levels 
between men in VALMA and VALTER, the latter divided into age categories <65 
years and ≥65 years, Figure 13. Men ≥65 years in VALTER reported lower un-
adjusted energy expenditure, less daily MET-hours, and less time spent at in vigorous 
physical activity compared to men in VALMA. Men in VALTER reported less time in 
vigorous physical activity then men in VALMA.  
 
 
 
Figure 13. Results from the Active-Q used in VALMA (men only, n=34) and VALTER studies (<65 years of 
age, n=64, and ≥65 years of age, n=79). Comparisons are made for variables of energy expenditure (not 
adjusted), total energy expenditure (adjusted to 24-hours), total daily MET-hours, daily time spent in 
light, moderate, vigorous and moderate-to-vigorous physical activity levels (LPA, MPA, VPA and MVPA) 
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5.2 PROSTATE CANCER PROGRESSION AND MORTALITY 
5.2.1 Characteristics 
Among study participants included in analysis of BMI and weight change, progression 
was experienced among 639 (14.6%) men. During the follow-up, 211 (4.1%) prostate 
cancer specific deaths and 628 (12.3%) deaths of any cause were recorded. The mean 
age of participants at time of diagnosis was 63.0 years and the mean BMI was 26.2 
kg/m
2
. Men with a high BMI were younger than men with a lower BMI. Distributions 
of exposure variables in Study I and II are shown in Table 5. Additional 
characteristics, including clinical data, are published in Paper I and II. 
 
Table 5. Exposure characteristics of study participants included in additional analysis by BMI at diagnosis 
 
 All BMI <25 BMI 25<30 BMI ≥30 P
4 
 (n=5,088) (n=1,881) (n=2,640) (n=567)  
 n (%) n (%) n (%) n (%)  
Weight change since diagnosis .000 
 No change 3,871 (76.1) 1,545 (82.1) 1,981 (75.0) 345 (60.9)  
 >5% Increase 771 (15.2) 239 (12.7) 437 (16.6) 95 (16.8)  
 >5% Decrease 446 (8.8) 97 (5.2) 222 (8.4) 127 (22.4)  
Total recreational MET-h  .000 
 <5 MET-h/day 1,190 (23.4) 400 (21.3) 604 (22.9) 186 (32.8)  
 ≥5 MET-h/day 3,898 (76.6) 1481 (78.7) 2,036 (77.1) 381 (67.2)  
Walking/biking after diagnosis .000 
 <20 minutes per day 1,103 (23.7) 355 (20.6) 573 (23.8) 175 (33.9)  
 ≥20 minutes per day 3,548 (76.3) 1,370 (79.4) 1,836 (76.2) 342 (66.2)  
Household work after diagnosis <.01 
 <1 hour per day 1,617 (34.9) 568 (33.0) 834 (34.7) 215 (41.7)  
 ≥1 hours per day 3,023 (65.2) 1,152 (67.0) 1,570 (65.3) 301 (58.3)  
Exercising after diagnosis .000 
 <1 hour per week 1,914 (41.2) 686 (40.0) 960 (39.8) 268 (51.9)  
 ≥1 hours per week 2,729 (58.8) 1,031 (60.1) 1,450 (60.2) 248 (48.1)  
 
5.2.2 Body Mass Index and progression 
No statistically significant associations were seen between BMI and prostate cancer 
progression in multivariable-adjusted analysis, Figure 14. For additional results, see 
the published Paper I. 
 
Figure 14. Crude, age-adjusted and multivariable adjusted Hazard Ratios (HR) with 95% 
Confidence Intervals (CI) are presented for prostate cancer progression by BMI-categories: <25 
(ref), 25<30 and ≥30 kg/m
2
. The multivariate model is adjusted for age at diagnosis, primary 
treatment, Gleason score, PSA, TNM-stage, smoking, and physical activity at age 50. 
HR 95% CI 
 
1.00 (reference) 
1.24 (1.04-1.47) 
1.12 (0.86-1.47) 
 
1.25 (1.05-1.48) 
1.15 (0.88-1.50) 
 
1.13 (0.92-1.38) 
1.11 (0.81-1.53) 
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5.2.3 Body Mass Index and mortality 
Increased rates of prostate cancer specific mortality were seen among men with a BMI 
≥30 kg/m2 compared to men with a BMI <25 kg/m2 in crude and age-adjusted analysis 
but not in multivariable adjusted models with and without lag-time. Men with a BMI 
>30 kg/m
2
 had statistically significantly higher overall mortality rates compared to men 
with a BMI <25 kg/m
2
 in both crude and adjusted models with and without lag-time. 
Results from Cox proportional hazard regression models are shown in Figure 15. 
Detailed information and additional results are published in Paper I. 
 
 
 
 
  
HR 95% CI 
 
1.00 (reference) 
1.02 (0.85-1.21) 
1.58 (1.25-2.01) 
 
1.05 (0.89-1.25) 
1.70 (1.34-2.16) 
 
1.05 (0.84-1.30) 
1.67 (1.24-2.25) 
 
1.12 (0.87-1.43) 
1.83 (1.31-2.56) 
Figure 15. Crude, age-adjusted and multivariable adjusted with and without lag-time. Hazard Ratios 
(HR) with 95% Confidence Intervals (CI) are presented for prostate cancer specific and overall 
mortality according to BMI-categories: <25 kg/m
2
 (reference), 25<30 kg/m
2
 and ≥30 kg/m
2
. 
Multivariable models are adjusted for age at diagnosis, primary treatment, Gleason score, PSA, TNM-
stage, smoking, and physical activity at age 50. 
HR 95% CI 
 
1.00 (reference) 
1.03 (0.76-1.38) 
1.52 (1.01-2.31) 
 
1.06 (0.79-1.43) 
1.61 (1.06-2.44) 
 
0.96 (0.66-1.40) 
1.22 (0.71-2.11) 
 
1.03 (0.68-1.55) 
1.11 (0.59-2.08) 
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5.2.4 Weigh change and mortality 
Prostate cancer specific mortality rates were higher among men who had reported a 
weight increase >5% since diagnosis compared to men who reported a stable weight. 
Men who reported a weight decrease >5% had higher prostate cancer specific mortality 
rates in crude, age-adjusted and multivariable adjusted models without lag-time but the 
association was not statistically significant after the introduction of 18-months lag-time. 
Overall mortality rates did not differ between men who reported a weight increase >5% 
from diagnosis and men with a stable weight. Men who reported a weight decrease 
>5% had higher overall mortality rates compared to men with a stable weight. Results 
from Cox proportional hazard regression models are shown in Figure 16. Additional 
results are published in Paper I. 
 
 
 
 
  
HR 95% CI 
 
1.00 (reference) 
1.17 (0.95-1.46) 
2.00 (1.60-2.50) 
 
1.24 (1.00-1.53) 
1.98 (1.58-2.48) 
 
1.19 (0.91-1.56) 
1.76 (1.32-2.33) 
 
1.26 (0.94-1.69) 
1.49 (1.06-2.08) 
Figure 16. Crude, age-adjusted and multivariable adjusted with and without lag-time. Hazard Ratios 
(HR) with 95% Confidence Intervals (CI) are presented for prostate cancer specific and overall 
mortality according to categories of weight change since diagnosis: No change (reference), >5% 
increase, >5% decrease. Multivariable models are adjusted for age at diagnosis, primary treatment, 
Gleason score, BMI at diagnosis, PSA, TNM-stage, smoking, and physical activity at age 50. 
HR 95% CI 
 
1.00 (reference) 
2.02 (1.47-2.78) 
1.98 (1.31-2.97) 
 
2.07 (1.50-2.85) 
1.94 (1.29-2.93) 
 
2.09 (1.40-3.11) 
1.73 (1.01-2.98) 
 
2.01 (1.31-3.10) 
1.36 (0.70-2.61) 
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5.2.5 Physical activity and mortality 
A clear indication of lower prostate cancer specific mortality can be seen for men with 
higher levels of all activities assessed: total recreational activity, walking or bicycling, 
household work and exercise. However, statistically significantly lower prostate cancer 
specific mortality rates were only seen in multivariable adjusted analysis for men who 
walked or bicycled ≥20 min/day compared to men who walked or bicycled less and for 
men who exercised ≥1 h/week compared to men who exercised less. Higher levels of 
all physical activity categories assessed were associated with lower overall mortality 
rates. Results from Cox proportional hazard regression models are shown in Figure 17. 
Additional results are published in Paper II. 
 
Figure 17. Crude, age-adjusted and multivariable adjusted with and without lag-time. Hazard Ratios 
(HR) with 95% Confidence Intervals (CI) are presented for prostate cancer specific and overall 
mortality by physical activity categories. Total recreational physical activity: <5 MET-h/day vs. ≥5 MET-
h/day; daily walking/bicycling: <20 min/day vs. ≥20 min/day; daily household work: <1 h/day vs. ≥1 
h/day; weekly exercise: <1 h/week vs. ≥1 h/week.  Multivariable models are adjusted for age at 
diagnosis, primary treatment, Gleason score, PSA, BMI at diagnosis and weight change. 
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5.3 PROSTATE CANCER RISK AND PSA-LEVELS 
5.3.1 Characteristics 
For detailed characteristics of all study participants divided by BMI-categories we refer 
to Table 1 in Study V. In brief, the mean age, BMI and PSA-level of study participants 
at baseline were 65.2 years, 26.4 kg/m
2
 and 4.3 ng/ml, respectively. A higher BMI was 
associated with younger age, less physical activity, lower level of education and 
increased stress levels. In total 452 men were diagnosed with prostate cancer during the 
follow-up. Of the diagnosed cancers, 158 (35%) were classified as low-grade and 294 
(65%) were classified as high-grade by Gleason score <7 or ≥7. 
 
5.3.2 Body Mass Index and serum PSA-levels 
Serum PSA-levels decreased with increasing BMI and among all men in the study, 
PSA decreased by 1.6% (95%CI: -2.1 to -1.1) for every one unit increase in BMI 
(kg/m
2
) in multivariable adjusted models. Larger decreases in PSA-levels were seen 
with increasing BMI-category, results from crude, age- and multivariable adjusted 
models from comparisons of BMI-categories are shown in Figure 18. In sub-group 
analysis of men who were diagnosed with prostate cancer during the follow-up and 
men who were not, no statistically significant decreases in serum PSA-levels were seen 
among men that were diagnosed while results for those not diagnosed were similar to 
the whole group. Linear regression splines of the association between BMI and serum 
log-PSA-levels confirm results from regression models. Figures and further details can 
be found in the manuscript for Study V.   
 
 
 
 
5.3.3 Body Mass Index and prostate cancer risk  
A higher rate of high-grade prostate cancer was seen among men with a BMI >35 
kg/m
2
 compared to men with a BMI <25 kg/m
2 
in the age-adjusted model. No other 
associations were seen for all, low-grade or high-grade prostate cancer. However, point 
estimates for high-grade cancer indicate increased rates with higher BMI. Detailed 
results and figures showing the standardized “survival” (i.e. cancer-free) probabilities 
obtained from Cox regression splines can be found in the manuscript for Study V.  
% change  95% CI 
 
1.00 (reference) 
-9.7 (-13.2 to -6.2) 
-21.9 (-27.4 to -16.4) 
-45.1 (-56.1 to -34.1) 
 
-5.4 (-8.8 to -2.1) 
-14.4 (-19.6 to -9.2) 
-32.7 (-43.2 to -22.3) 
 
-3.7 (-7.2 to -0.2) 
-11.6 (-17.1 to -6.2) 
-32.3 (-43.2 to -21.4) 
Figure 18. Results from crude, age-adjusted and multivariable adjusted multiple linear regression 
models of percent change in baseline PSA-levels with 95% confidence intervals by BMI-category. 
Multivariable models are adjusted for age at baseline, time spent on a moderate-to-vigorous 
physical activity level (h/day), education, smoking status, stress and family history of prostate 
cancer. 
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6 DISCUSSION 
 
6.1 VALIDATION STUDIES  
Making inferences about an association between an exposure and an outcome is 
directly dependent of the validity of the exposure and outcome assessments. The 
validity tells us how well a method is able to measure what is supposed to be measured 
implies reliability, or reproducibility, which ensures us that we will get the same results 
with repeated measurements. The importance of a well-designed validation study 
should not be underestimated.   
 
 
6.1.1 Methodological considerations 
6.1.1.1 Study design 
The study design of Study III and IV are similar. Sample sizes are in the same range as 
previous studies using pedometers, accelerometers or doubly labeled water.
36, 120
 While 
pedometers and accelerometers are feasible to use in larger samples, DLW is expensive 
and requires more work which limits large scale use. Both studies include relative short 
periods of data collection although ideally, the time-frame of measurements by the 
reference method used should mirror the time-frame assessed by the method being 
validated. Active-Q assessed habitual physical activity during the past year (Study III) 
and the past months (Study IV) while the reference methods assessed the average daily 
total energy expenditure during 11 days (DLW) and the average physical activity 
during 12 days (GENEA) at approximately the time of responding to the questionnaire. 
To better mirror a similar time-frame, repeated measures with the reference method 
over a longer period of time, before responding to the questionnaire, would have been 
desirable. This was, however, not possible due to practical reasons. The timing of 
repeated assessments for determining reproducibility is also important to consider. The 
time period between assessments must be long enough so that the participants do not 
remember their previous answers, which potentially can inflate the reproducibility due 
to correlated errors, but needs to be short enough so that the true physical activity 
behavior has not changed due to, for example, seasonal variation.  
 
Within the VALTER-study, a calibration of the GENEA accelerometer to classify 
output into different intensity levels was performed. Monitor output was compared to 
direct observation of specific activities with defined MET-levels. The range of MET-
values of included activities was quite narrow, ranging from 1.5 to 5, and included 
mainly activities of locomotor movement (e.g. walking, running). Ideally, a broader 
range of different activities, also including higher MET-values, should have been 
used.
121 
Equation patterns based on locomotor movement tend to lead to 
underestimations of physical activity when compared to lifestyle activities.
58
 Although 
we created cut-offs and defined the measured activity by intensity to enable 
comparisons to Active-Q, it has been suggested that researchers should focus more on 
raw data output and discontinue the development and use of cut-points to define 
intensity categories .
121
 The use of raw acceleration information that has not been 
transformed according to monitor specific equations, allows for direct comparison 
between different monitors. 
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6.1.1.2 The use of MET-values 
A major limitation when using MET-values (paragraph 2.3.1.1) to represent the energy 
cost of specific activities is that the defined value of 1 MET as 1 kcal·kg
-1
 body 
weight·h
-1
 or conversely an oxygen consumption of 3.5 ml O2·kg
-1
 body 
weight·minute
-1
, is derived from a sample of adult and normal weight men.
122
 This may 
not be suitable for other individuals or populations. Assuming the same MET-value for 
a specific activity for all individuals neglects variations in both mechanical and 
metabolic efficiency and may potentially lead to misclassification of energy 
expenditure and time spent at different intensity levels.
19
 
 
6.1.1.3 Choice of reference method 
The choice of reference methods is critical and depends on what construct of physical 
activity you intend to validate, for example if you aim to validate constructs of total 
physical activity, time spent at a certain intensity level or energy expenditure. No 
matter what construct you aim to validate, it is important to choose a reference method 
with uncorrelated errors to the method you are validating. If the two methods have 
correlated errors, validity may be overestimated. In this thesis work, self-reported 
physical activity has been compared to three different objective physical activity 
methods including DLW, pedometers and accelerometers, covering a broad range of 
activity constructs. 
 
6.1.1.4 Validity 
Within a validation study, there are many different concepts of validity. The type of 
validity assessed depends both on the type of method being validated and the choice of 
reference method. Construct validity refers to the association between physical activity 
measured with any type of method and a physiological variable related to physical 
activity, e.g. aerobic capacity. Relative validity is assessed when a method is validated 
against a similar instrument, for example comparing a questionnaire to another self-
reported instrument such as a diary. Since two self-reported methods are subject to 
correlated errors, a high correlation does not necessarily mean that the methods are 
valid. Criterion validity is determined when validating a self-reported method against 
an objective instrument, for example comparing total physical activity levels from a 
questionnaire to results from accelerometers. Lastly, absolute validity is assessed when 
comparing results of the same absolute outcome assessed with the method under 
validation and measured using an objective instrument, for example total energy 
expenditure assessed by a questionnaire and measured by DLW. Self-reported 
instruments, e.g. physical activity questionnaires, usually show poor to moderate 
criterion validity and lower absolute validity.
48
 
 
High accuracy implies absence of both random errors that affect precision, and absence 
of systematic errors that affect validity. While the magnitude of random error is 
inversely proportional to sample size, systematic errors may affect validity negatively 
even in very large samples. If a systematic error affects all individuals in a study 
population, it can for example affect the individuals’ absolute results of energy 
expenditure, it may still allow for correct ranking of the individuals according to their 
energy expenditure. Such non-differential systematic error is less critical than a 
systematic error that differs between groups in a study population.  
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6.1.1.5 External validity 
The external validity describes how generalizable our results are to other populations. 
Study participants in Study III were young and mainly females while participants in 
study IV were older men recruited within a specific cohort. The two studies represents 
very different groups but are both self-selected and participants may be more interested 
and motivated than the general population. Our results of validity and reproducibility 
may therefore be somewhat overestimated compared to if we used a random sample 
from the general population. 
 
 
6.1.2 Main findings and interpretation 
6.1.2.1 Validity 
The Active-Q questionnaire showed moderate correlations to the gold standard DLW 
for assessment of total energy expenditure adjusted to 24-hours (r=0.52). The 
correlation when comparing crude energy expenditure assessed by Active-Q was not 
surprisingly lower (r=0.42). This variable does not represent total energy expenditure 
during 24-hours which the DLW measure does. Our results are line with the majority of 
validation studies comparing total energy expenditure from a physical activity 
questionnaire and DLW with correlation coefficients ranging between r=0.14-0.64.
36, 38, 
123
 However, all physical activity questionnaires previously validated against DLW 
have, to the best of our knowledge, been paper-based making direct comparison to the 
web-based Active-Q difficult.  
 
The validity of self-reported total energy expenditure is generally high when compared 
to a gold standard method but should be interpreted with caution. The total energy 
expenditure depends to a large degree on the individual’s body weight and therefore 
incorporates an element of BMR, which explains a lot of the variation in energy 
expenditure and is likely to yield high correlations by definition. Physical activity only 
explains a small part of the variation in our total energy expenditure. It is therefore not 
surprising that when comparing total MET-h from Active-Q, which does not include 
BMR, and total energy expenditure from DLW, the resulting correlation is lower 
(r=0.28) than those for variables of energy expenditure. Similarly, correlation 
coefficients comparing energy expenditure assessed with Active-Q to total daily steps, 
representing physical activity behavior, are also low (r = 0.07 and r = -0.12) and not 
statistically significant. A comparison of total MET-h from Active-Q and daily steps 
yielded a higher correlation coefficient (r = 0.20) as the latter compares similar 
constructs of activity.  
 
The Bland-Altman plots did not show clear trends of bias across the range of total 
energy expenditure or any substantial differences between men and women. No 
systematic over-reporting of energy expenditure was seen and the mean difference 
between total energy expenditure adjusted to 24-hours from Active-Q and DLW was 
small (447kJ). However, the Bland-Altman plots show that the total energy expenditure 
of two individuals (above +2SD of the mean difference) was clearly overestimated in 
Active-Q. One individual was obese (BMI = 44.7kg/m
2
) and an example of the 
limitations with using standardized MET-values when calculating energy expenditure. 
The other individual was a professional athlete who reported more than 10 hours of 
weight training, jogging and athletics per day. This exemplifies another limitation of 
MET-values and pre-defined response alternatives as the intensity level of any activity 
reported is assumed to be constant during the whole reported time interval. This is, 
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however, most likely not the case for long athletic sessions where the more intense 
activity is probably broken up by less intense periods.  
 
For calculations of total energy expenditure from DLW, a standard respiratory quotient 
(RQ) of 0.85, suitable in a population with a western diet where 30-35% of the energy 
intake comes from fat, was used. This corresponds to the intake among study 
participants in VALMA.
103
 Using an RQ that is not suitable for the macronutrient 
intake in a population will have negative effects on the accuracy of measurements. 
 
For time spent at a vigorous activity level, a moderate correlation coefficient was seen 
between Active-Q and accelerometer measurements (r=0.54). Lower correlations were 
seen for time spent at light, moderate and moderate-to-vigorous activity levels (r=0.27-
0.35). The correlations were somewhat lower among men <65 years of age and 
somewhat higher among older men.  Our results are in line with the validity seen for 
different constructs of activity in other questionnaires compared to accelerometer 
data.
36, 124, 125
 However, most previous validation studies have been performed in 
younger populations. One systematic review focusing on physical activity 
questionnaires for elderly (>55 years) showed varying results of validity and none of 
the studies included validated time spent at different intensity levels making 
comparisons to our results difficult.
126
 Among adults >65 years of age, Siebling et al.
127
 
showed poor correlations (r=0.01-0.27) between time spent at MET-levels 
corresponding to the definition of light, moderate and vigorous activity in our study.  
 
A clear trend of increased over-reporting of time spent performing moderate and 
vigorous activities was seen with increasing levels of moderate and vigorous activity in 
the Bland-Altman plots. A corresponding under-reporting of light activities was seen 
among men reporting lower levels of light activity. The mean difference between the 
methods was fairly large in relation to the total time spent in moderate, vigorous and 
moderate-to-vigorous activity, but smaller for light activity. Over-reporting of time 
spent moderate-to-vigorously active and under-reporting of sedentary time have been 
seen previously in comparisons of questionnaire and accelerometer data, although the 
mean differences between methods were smaller than in the present study.
128
 One 
explanation for the low agreement between Active-Q and accelerometer data may be 
the inability of accelerometers to capture all activities. Movements from activities such 
as bicycling or swimming are not measured by the accelerometer and could contribute 
to the discrepancy between the methods. Accelerometers also fail to capture static and 
non-ambulatory activities, for example carrying a heavy load or walking uphill.
45
 This 
would, however, not have been captured in Active-Q either and should not have a 
major impact on our results. The discrepancy between the time-period reflected in 
Active-Q and the two weeks of accelerometer measurements may also have contributed 
to the differences. 
 
Comparisons of results from Active-Q measurements in both Study III (men only) and 
IV (men divided into sub-categories of <65 and ≥65 years of age), showed similar 
levels of energy expenditure and physical activity. However, men ≥65 years of age 
reported lower levels or total MET-h and crude energy expenditure compared to men 
<65 years in the same study and men in the other study. This difference may partly be 
explained by the assessment of occupational activity. More men <65 years of age are 
likely working compared to older men and will report the duration, frequency and 
intensity of working time. While the lack of occupation is thought to lead to reporting 
of more leisure time activities, this replacement may not be equal to time reported for 
work. The lower level of crude energy expenditure may also partly be explained by 
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older men having a lower BMI, i.e. a lower weight, than younger men leading to lower 
estimations of energy expenditure in this group. 
 
6.1.2.2 Reproducibility 
The ICCs for energy expenditure with and without adjustments to 24-hours from 
Active-Q were 0.74 and 0.87, respectively. For total MET-h and time spent at different 
activity levels, ICCs ranged between 0.51 and 0.66. The higher agreement for variables 
of energy expenditure is most likely due to the fact that variability in energy 
expenditure is largely explained by the individual’s BMR. Nevertheless, our results are 
similar to those of other physical activity questionnaires, the median ICC in a recent 
review was 0.68.
36
 The same review also showed that shorter time periods between 
assessments were associated with higher ICCs. 
 
 
 
6.2 PROSTATE CANCER RISK, PROGRESSION AND MORTALITY  
6.2.1 Methodological considerations 
6.2.1.1 Study design  
A major limitation to the PROCAP-study (Study I and II) is the left-truncation of 
study participants, i.e. the conditioning on being alive 5 to 10 years after prostate cancer 
diagnosis for inclusion in the study. The left-truncation time (i.e. the time from 
diagnosis to inclusion) only depends on time from diagnosis and is most likely random 
and independent of the survival time. The problem of left truncation is illustrated from 
a causal inference point of view in the Figure 19. In this DAG, X is the exposure (BMI, 
weight change, or physical activity), D1 is an indicator of whether the patient died 
before the truncation point (i.e. inclusion), and D2 is an indicator of whether the patient 
died at a specific later point in time (i.e. during the follow-up). All potential measured 
and unmeasured confounders are denoted by U. To simplify the argument we assume 
that all variables are binary (0/1) with 1=exposed/dead. In the situation of left 
truncation we cannot study the association between X and D1, but are forced to study 
the association between X and D2, conditional on D1 being equal to 0 (i.e. alive). Using 
standard arguments from the causal inference literature
129
 we induce a non-causal 
association component between X and D2 through D1. However, it can be argued that 
this association is likely to have the opposite sign as the true causal effect, thereby 
forcing the association towards a null effect. Suppose that we observe, for a given 
patient with D1=0, that X=1 (exposed). Generally, X=1 increases the probability of 
D1=1, so to “explain” why D1=0 for this given patient, the probability of U=0 must 
increase. This, in turn, increases the probability of D2=0. Hence, by conditioning on 
D1=0 we are likely to induce an inverse association between X=1 and D2=0.  
 
 
 
Figure 19. DAG illustrating bias due to left truncation. 
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While exposure assessment in Study V was done prospectively at baseline, a 
limitation to Study I and II is that the assessment of exposures in PROCAP was 
made in retrospect several years after the prostate cancer diagnosis. Erroneous recall 
of information may lead to misclassification of the true exposures which in turn may 
lead to an invalid estimate of the associations between exposures and outcomes. 
However, we believe that neither progression nor mortality is likely to have had a 
major impact on the reporting of exposure variables. Potential misclassification is 
therefore likely to be non-differential, biasing the estimates towards a null effect.  
 
Random error does inherently occur in a sample randomly selected from the whole 
population, i.e. random variation may occur due to chance at selection also in 
population based studies such as PROCAP and STHLM-2. Random error leads to a 
lack of precision in estimates and uncertainty of measurements. The magnitude of 
random error is inversely proportional to sample size. 
 
6.2.1.2 Reversed causality 
Reversed causality is usually defined as the situation occurring when an outcome 
precedes and causes an exposure instead of the exposure causing the outcome.
5
  
However, in studies of body weight and mortality, the term reversed causation has been 
used to describe the situation when both the exposure and outcome are affected by a 
third factor, e.g. weight loss, caused by an underlying illness.
130
 Even though this is 
rather a case of confounding (paragraph 2.1.1.2), the concept of reversed confounding 
has become commonly used to describe when an association between body weight and 
mortality is biased by weight-loss caused by pre-existing illness.
131
 We performed 
sensitivity analysis using a 18-month long lag-time and men who experienced the 
outcome (death in Study I and II, and prostate cancer incidence in Study V) within 18-
months of exposure assessment were excluded from analysis to avoid bias from 
reversed causation.  
 
6.2.1.3 Internal and external validity 
Internal validity refers to the validity of results within the study population and is a 
prerequisite for external validity which refers to how generalizable the results are to 
other populations. The internal validity is threatened by confounding, selection bias and 
information bias.
5
 
 
6.2.1.4 Confounding 
Confounding (paragraph 2.1.1.2) is the effect of a third factor on an exposure-outcome 
association and not controlling for confounding may bias the observed association. 
While confounding can be addressed directly in the study design (e.g. by randomization 
or matching), it can also be addressed at the analysis stage by controlling for known 
and measured confounders in statistical models. Adjustment of multiple confounders 
can be done simultaneously in regression models. To assess potential confounding by 
covariates in Study I, II and V, we tested if the covariates were statistically associated 
with both the exposures and the outcomes using linear regression and Cox proportional 
hazards models. In the end, the final inclusion of covariates in statistical models was 
based both on results of associations and subject matter knowledge. Even if we try to 
control for confounding, there may always be unknown, unmeasured or residual 
confounding affecting the results. Residual confounding due to measurement errors 
within measured confounder variables may remain even after adjustments.  
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6.2.1.5 Selection bias 
Selection bias occurs when the association between an exposure and an outcome is 
different among study participants compared to the whole population which also 
include those who did not participate in the study. Selection bias is a threat to the 
internal validity as well as the external validity as it limits generalizability of the results 
to the other populations. Results in Study I, II or V are unlikely affected by selection 
bias to any large extent as both studies are population based with high participation 
rates and complete follow-up.  
 
6.2.1.6 Information bias 
The most common type of information bias is misclassification bias. Differential 
misclassification is information bias within the exposure variable that is influenced by 
disease status, i.e. it may occur if the exposure is assessed after the outcome and the 
outcome affects recall of the exposure, or the other way around. Differential 
misclassification of the exposure should not be of major concern in Study I, II or V 
where the exposure has been assessed before the outcomes with one exception. In 
analysis of prostate cancer progression (Study I), the exposure status was assessed after 
the progression event. However, we do not believe recall bias is an issue here since any 
event of progression is unlikely to have influenced reporting or neither body weight nor 
physical activity.  
 
Even in studies where the exposure is measured before the outcome, non-differential 
misclassification may occur. If the exposure variable is dichotomous, non-differential 
misclassification may attenuate the results but when the exposure variables have three 
or more levels we cannot be sure of the direction of the potential bias. Measurement 
errors may also occur when continuous exposure variables are analyzed as categorical 
using arbitrary cut-offs. Categorization is a balance between creating relevant cut-offs 
and groups that have different enough exposure levels, at the same time as statistical 
power is ensured by a sufficient number of subjects in each category. 
 
Exposures in Study I and II are self-reported retrospectively while BMI in Study V is 
based on self-reported current weight and height. Although correlations between self-
reported and measured weight and height are strong, the long-term recall is influenced 
by current weight.
132, 133
 Over-reporting of height, under-reporting of weight and 
consecutive under-estimations of BMI, is generally seen.
134
 Increased under-
estimations of weight are seen with increasing BMI.
135, 136
. Individuals who have 
experienced a large reduction in weight tend to over-estimate their previous weight in 
long-term recalls.
137
 The validity of self-reported changes in weight is not well studied 
but errors in self-reports of weight change appear to be random.
138
 The use of BMI as a 
proxy for body fat is also a limitation and has been discussed in paragraph 2.2. 
 
Self-reported physical activity is commonly over-estimated.
39
 This may be due to social 
desirability and memory bias, the latter more common among older individuals who 
may have cognitive difficulties in recalling activities.
40
 Although the physical activity 
questionnaire used in Study II has been previously validated, difficulties of having to 
recall information from several years ago may have increased misclassification. Self-
reported questionnaires to assess physical activity are discussed in paragraph 2.3.3.1. 
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6.2.2 Main findings and interpretations 
6.2.2.1 Body Mass Index and prostate cancer progression and mortality (Study I) 
BMI was not associated to progression or prostate cancer specific mortality. However, 
point estimates indicate increased rates of progression and cancer specific mortality 
among men in the higher categories of BMI compared to men in the reference group 
(<25kg/m
2). Higher overall mortality rates were seen among men with a BMI ≥30 
kg/m
2
 compared to the reference. 
 
The consistent association between a high BMI and an increased risk of aggressive 
prostate cancer suggest that BMI may have an impact on progression rather than 
tumor development.
77
 Most previous studies, but not all
139
, have found associations 
between a high BMI and an increased risk of biochemical recurrence.
78, 92, 140-144
 In 
contrast to the previous findings, we did not find any association between BMI and 
progression. Higher rates of prostate cancer specific mortality with increasing BMI 
have also been reported repeatedly.
78, 145-148
 The association has been suggested to be 
more pronounced in men with aggressive disease.
79
 Since our study only included 
men diagnosed with localized prostate cancer, the latter may explain why we, in 
contrast to other studies, did not find an association between BMI and prostate cancer 
specific mortality. The increased rates of overall mortality we saw among men with a 
high BMI, could be a result of an increased risk of for example cardiovascular disease 
which is strongly associated with high BMI. 
 
Several possible mechanisms linking adiposity and prostate cancer have been 
proposed with the main hypothesis being that increased adiposity causes hormonal 
and metabolic changes. These changes include alterations of pathways for insulin and 
insulin-like growth factors (IGFs), sex hormone levels, and altered adipokine 
signaling.
149
 High BMI is associated with hyperinsulinemia that through the reduction 
of IGF-binding proteins generates increased serum levels of IGF-I, which promote 
tumor development.
150
 Additionally, high adiposity leads to lowered androgen levels 
and decreased serum testosterone, the latter associated with an increased risk of 
aggressive prostate tumors.
151
 Altered levels of adipokines as a result of obesity will 
affect levels of leptin and adiponectin that may promote tumor development.
149
 
Similar mechanisms are most likely involved in the associations between weight 
change and physical activity, and prostate cancer. 
 
6.2.2.2 Weight change and mortality (Study I) 
A weight increase of >5% since diagnosis was associated with increased prostate 
cancer specific mortality rates compared to the reference group of men having reported 
a stable weight. A weight reduction >5% was associated with higher prostate cancer 
specific mortality in multivariable adjusted models without lag-time but the association 
did not remain in sensitivity analysis. The opposite was seen for overall mortality rates 
that were not statistically significantly different for men who increased in weight but 
higher among men who decreased in weight compared the men who kept a stable 
weight. 
 
Large weight gain during adulthood has been associated with an increased risk of 
biochemical recurrence and aggressive or fatal prostate cancer.
90-92
 Few studies 
looking at the effects of weight change in close approximation to or after the cancer 
diagnosis have been published. One study has shown an association between weight 
gain 5 years before and 1 year after a prostate cancer diagnosis and an increased risk 
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of cancer recurrence.
93
 Another study showed that a large weight gain in the year 
before a radical prostatectomy increased the risk of biochemical recurrence compared 
to maintaining a stable weight.
94
 In line with previous findings, we showed increased 
rates of prostate cancer specific mortality among men who experienced a larger 
weight gain compared to men who kept a stable weight. The results were statistically 
significant also in sensitivity analysis which strengthens our finding and indicates that 
the weight gain was unlikely to have been caused by the disease itself or other illness. 
An increased rate of prostate cancer specific mortality was also seen among men who 
decreased in weight but the attenuation of this association in sensitivity analysis 
indicate the weight loss may have been due to illness, i.e. reversed causality 
(paragraph 6.2.1.2). Hormonal and metabolic pathways are altered by the level of 
adiposity and therefore also likely to be affected by a weight change once a tumor has 
developed. Suggested mechanisms for the association between adiposity and prostate 
cancer are described in paragraph 6.2.2.1. 
 
Our results are based on self-reported weight change and we do not know whether 
this was intentional or not. It is possible that an intentional weight change has 
different effects than an unintentional which may be caused by other factors such as 
disease, health issues, or malnutrition. While intentional weight loss among 
individuals with a high BMI may have positive effects on health and survival, an 
unintentional weight loss may be the result of poor health and thereby be associated 
with higher mortality. Weight maintenance or intentional weight change to improve 
health after diagnosis may be used as complements to treatment to improve survival.  
 
6.2.2.3 Physical activity and mortality (Study II) 
Lower prostate cancer specific mortality rates were seen for men who walked or 
bicycled ≥20 min/day and for men who exercised ≥1 h/week compared to men who 
walked, bicycled or exercised less. Higher levels of total recreational activity (≥5 MET-
h/day), walking or bicycling (≥20 min/day), household work (≥1 h/day) and exercise 
(≥1 h/week) were associated with lower overall mortality rates compared to lower 
levels of activity in all categories. 
 
Consistent evidence has linked increased physical activity to reductions in all-cause 
mortality among cancer survivors but evidence for prostate cancer specific mortality is 
still inadequate.
95
 While physical activity has been inversely associated with prostate 
cancer risk
97
, the effects of post-diagnostic physical activity on progression and 
mortality have only been investigated in two previous studies to the best of our 
knowledge. Kenfield et al.
98
 showed reductions in both all-cause and prostate cancer 
specific mortality among men who engaged in vigorous physical activity ≥3 h/week 
compared to men who performed the activity <1 h/week. Higher levels of walking were 
associated with decreased all-cause mortality and indicated a decrease of prostate 
cancer specific mortality. Richman et al.
99
 showed lower rates of progression among 
men who walked briskly for ≥3 h/week compared to men walking less and at an easier 
pace. Independent of walking duration, the authors also showed that walking at brisk 
pace was associated with a decreased progression rate compared to walking at an easier 
pace. Our results are in line with the previous studies, although we see positive effects 
at lower levels of physical activity, and show lower overall and prostate cancer specific 
mortality rates among physically active men.  
 
The effects of physical activity on prostate cancer progression seem to partly work 
through similar, but opposite, mechanisms as BMI.  Suggested mechanisms include 
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effects of physical activity on pathways of adipokine signaling, insulin and insulin-like 
growth factors (IGFs), and inflammation.
152
 Alterations in adipokine levels as a result 
of obesity have been associated to tumor development.
149
 Physical activity may 
counteract this effect. Increased aerobic fitness, i.e. a favorable change in body 
composition, following physical activity has been correlated to beneficial effects on 
adipokine levels in men with prostate cancer.
153
 Regular exercise may also affect the 
serum IGF-axis resulting in lower levels of serum insulin and IGF-1. Increased levels 
of IGF binding protein-1 in vivo has been associated with reduced proliferation and 
increased apoptosis of prostate tumor cells in vitro.
154, 155
 Serum extracted directly after 
strenuous exercise has also been shown to reduce proliferation of prostate tumor cells 
in vitro.
156
 This indicates that physical activity may have acute effects on tumor growth. 
Lastly, inflammation has been suggested to play a role in prostate cancer development 
and progression.
157
 Physical activity may have beneficial effects on inflammation by 
reducing levels of pro-inflammatory C-reactive protein.
158
  
 
6.2.2.4 Body Mass Index and serum PSA-levels (Study V) 
Higher BMI was associated with decreased serum PSA-levels among all men in the 
study. While an association was seen for men who were not diagnosed with prostate 
cancer during the follow-up, no association between BMI and PSA-levels was seen 
among men who were diagnosed during the follow-up. 
 
Our results are in line with most previous studies that have found and established an 
inverse association between BMI and PSA-levels among men without prostate 
cancer.
75, 76, 80-86
 An increasing BMI has also been associated to less rapid increases in 
PSA-levels as compared to PSA-changes in men with lower BMI.
159
 Some studies 
have, however, found no association between BMI and PSA-levels.
89, 160, 161
 Studies 
of the association among men with prostate cancer are fewer and the association less 
clear. Three cohort studies showed associations between higher BMI and lower levels 
of pre-operative serum PSA among men who underwent radical prostatectomy.
76
 
Another study found no association.
87
 In line with the latter study, we could not see 
an association between BMI and serum PSA among men who were diagnosed with 
prostate cancer during the follow-up. However, baseline PSA-levels were higher 
among men who were diagnosed during the follow-up compared to men who were 
not. 
 
A suggested explanation for the association between BMI and PSA-levels is 
hemodilution, i.e. a dilution of the total PSA amount due to larger plasma volume. 
This explanation is strengthened by several studies showing associations between 
BMI and plasma volumes as well as BMI and serum PSA concentrations concomitant 
to not seeing any differences in PSA-mass by BMI.
76, 82
 Another explanation is 
decreased levels of circulating androgens, which are important for normal growth and 
differentiation of the prostate, seen with increasing BMI.
162
  
 
Factors that may influence PSA-levels are important to assess as most prostate 
cancers today are detected through a biopsy following the results of a PSA-test. If 
hemodilution due to a high BMI masks an increased PSA-mass caused by a growing 
tumor, detection of the cancer may be delayed. Delayed cancer detection in men with 
a high BMI might also be a result of difficulties to biopsy since a high BMI has been 
associated to increased prostate weight and volume.
85, 88, 89
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6.2.2.5 Body Mass Index and prostate cancer risk (Study V) 
We saw no association between the risk of prostate cancer and BMI. However, point 
estimates for high grade prostate cancer indicate increased rates among men in the 
higher BMI-categories compared to men with a BMI <25 kg/m
2
.   
 
Prostate cancer is hormone related and likely to be linked to anthropometric factors. 
The association between BMI and prostate cancer risk is therefore well studied but 
results are, however, inconsistent.
69
 While BMI has been positively associated with 
the risk of advanced or fatal prostate cancer, inverse associations with overall risk and 
the risk of localized disease have been shown.
70-74, 163
 The association between BMI 
and risk of high-grade prostate cancer may be explained by a poorer prognosis 
following delayed detection and diagnosis.
76
 In line with previous findings, we found 
no association between BMI and the risk of overall or low grade prostate cancer. Our 
results indicate an increased rate of high-grade prostate cancer among men with a BMI 
≥35kg/m2 compared to men with a BMI <25kg/m2. The wide confidence intervals 
around point estimates in sub-category analysis of low- and high-grade prostate cancer 
indicate uncertainty within our measurement. This is most likely due to the short 
follow-up time which limits the power in statistical analysis. Longer follow-up time 
would increase the number of incident prostate cancers and the power of statistical 
analysis.  
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7 CONCLUSIONS 
 
Study I and II 
In a large prospective cohort study of more than 5,000 men diagnosed with localized 
prostate cancer we found: 
 
 No association between BMI and prostate cancer progression  
 That men with a BMI ≥30 kg/m2 had an 83% increased overall mortality rate 
compared to men with a BMI <25 kg/m
2
   
 No association between BMI and prostate cancer specific mortality  
 That men who experienced a reduction in body weight by >5% after diagnosis 
had an almost 50% higher overall mortality rate compared to men who kept a 
stable weight  
 That men who experienced an increase in body weight by >5% after diagnosis 
had a doubled prostate cancer specific mortality rate compared to men who kept 
a stable weight  
 That men who reported higher levels of total recreational activity, walking or 
bicycling, household work and exercise had approximately 20-35% lower 
overall mortality rates compared to less active men 
 That men who reported higher levels of walking or bicycling and exercise had 
30% lower prostate cancer specific mortality rates compared to less active men 
 
 
Study III and IV 
The validity of the web-based physical activity questionnaire Active-Q was assessed in 
two validation studies by comparing results from the questionnaire to the three different 
reference methods:  doubly labeled water, pedometers and accelerometers. Our results 
showed: 
 
 Moderate validity for assessment of total energy expenditure compared to the 
doubly labeled method 
 Poor validity for assessment of total MET-h compared to daily steps from 
pedometers 
 Moderate validity for assessment of time spent at light, moderate, vigorous and 
moderate-to-vigorous physical activity levels compared to accelerometers 
 Good reproducibility with regards to total energy expenditure, total MET-h and 
time spent at different activity levels 
 
 
Study V 
In a population based prospective cohort study of approximately 15,000 men we found: 
 
 That men with a higher BMI had reduced levels of serum PSA 
 No association between BMI and prostate cancer risk 
 A suggestive association between high BMI and high-grade prostate cancer 
 50 
8 FUTURE PERSPECTIVES  
 
Results from this thesis have added small pieces to the large and complex puzzle that is 
prostate cancer etiology and survival after a prostate cancer diagnosis. The association 
between lifestyle factors and prostate cancer remains complex but it is clear that 
lifestyle matters. Maintenance of a healthy weight and being physically active provide 
strategies for men to improve their own health and survival. 
   
The high incidence of prostate cancer is a major public health concern. To date, few 
studies have been able to study the impact of lifestyle after diagnosis due to a lack of 
data. The PROCAP-study offered a unique opportunity to assess the impact of lifestyle 
on prostate cancer progression and mortality in a large group of men diagnosed with 
localized prostate cancer. While this thesis work has focused on the impact of BMI, 
weight change and physical activity, there may be other lifestyle factors, such as diet or 
stress for example, that are equally important to study in the future.  
 
In addition to previous studies, we were able to study the effects of weight change after 
prostate cancer diagnosis on mortality. However, we were not able to separate 
unintentional from intentional weight loss. Intentional weight loss to reach a body 
weight within the normal range have positive effects on cardiovascular mortality and 
could potentially have beneficial effects also on prostate cancer specific mortality as it 
counteracts the effects of high BMI. Future intervention studies looking at the effects of 
intentional weight change would therefore be an interesting next step. 
 
Co-occurring with the high incidence of prostate cancer is the high prevalence of 
overweight and obesity. Since high BMI has an effect on PSA-levels, there is a need for 
studies aiming to improve guidelines on how to integrate information on BMI in the 
interpretation of PSA-values. If early detection of prostate cancer among overweight 
and obese men is hindered by the association between BMI on PSA, it is of great public 
health concern and needs to be addressed. 
  
We also showed that physical activity reduced both overall- and prostate cancer 
specific mortality rates. Very reasonable levels of activity, 20 minutes of walking or 
bicycling per day or more and one hour of exercise per week, was enough. However, 
engaging in more physical activity than that may lead to even stronger effects. It is also 
possible that aerobic activities may have different effects than muscle strengthening 
activities. Future intervention studies randomizing men diagnosed with prostate cancer 
into different types of activity at different durations would be the next step to clarify 
what impact different types and durations of physical activity have on tumor 
progression and survival as well as quality of life for this group of patients. 
 
We all know that physical activity is good for our health and yet it is so hard to get off 
the couch and into our running shoes. When faced with a cancer diagnosis, we may 
however reevaluate our lives and decide that it is time for a change and actually 
implement that change! Many ask themselves the question “What can I do to survive 
my cancer?” Now, the health care system has an important role in informing men about 
potential lifestyle changes that may help improve survival and quality of life. This is a 
golden opportunity to help the individual patient but also to improve public health in 
general.  
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Inconsistent associations between results from different studies can sometimes be 
attributed to methodological flaws and difficulties in assessing exposures. Physical 
activity is most often measured through self-reported questionnaires in large studies 
and it is important to use a validated method. The web-based physical activity 
questionnaire Active-Q that has been described in this thesis work provides a valid 
assessment method and is included in several large scale epidemiological studies, 
including the LifeGene, Karma, STHLM-2 and STHLM-3studies. To date, more than 
100,000 study participants have responded to the questionnaire.  
 
During the past years, using the Web to perform large data collections has become 
increasingly common. The days of using paper-based questionnaires that had to be 
printed, mailed to study participants at a high cost, filled-out very meticulously, mailed 
back to the researchers, checked for completeness and scanned into digital format are 
soon history. Instead, here are the days of efficient questionnaire design in web-based 
programs where automatic checks for completeness can be implemented, there are no 
costs for printing, distribution or scanning of the questionnaire and results are 
automatically stored in digital format. The rapid technology development has also 
enabled data collections through the use of smartphones and applications (“apps”). 
Technology will continue to improve and change the way we collect data and also the 
type of information we collect. We have a potential gold mine of information regarding 
lifestyle already in our smartphones; did you know most smartphones have a built in 
accelerometer? Now we just have to find a way to implement this in research. Imagine 
what we could do! 
 
My hope is that this thesis will contribute to the field of cancer research as well as 
encourage the use of validated questionnaires to assess physical activity in future 
studies.  I also hope that our findings will contribute to the lives of the many men with 
prostate cancer, giving them means to influence their own survival and encourage them 
to have a healthy and physically active lifestyle.  
 
 
Drawing by Nils Bonn 
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